The protein related to Pseudoxanthoma Elasticum regulates the purinergic system. New insight on the ABCC6 transporter by Martinelli, Fabio
 
 
                                                        
UNIVERSITY OF SALERNO 
DEPARTMENT OF CHEMISTRY AND BIOLOGY 
and 
UNIVERSITY OF BASILICATA 
DEPARTMENT OF SCIENCE  
 
Ph.D. in Chemistry - XXXI Cycle 
BIO/10 - Biochemistry 
 
Doctoral Thesis in  
“The protein related to Pseudoxanthoma Elasticum 
regulates the purinergic system. 
 New insight on the ABCC6 transporter” 
 
Ph.D. Coordinator: 
Prof. Gaetano Guerra 
                                                                                     Ph.D. Student: 
     Dr. Fabio Martinelli 
Tutor:                                                                             
Prof. Faustino Bisaccia 
Co-Tutor: 
Prof. Magnus Monné 
 














To my parents, 
to my brother, 
to my grandfather, 





















“The scientist is not the man 
who provides the true answers; 




















2(-ΔΔCt)                               Fold Change 
5’UTR                               5’ Untranslated region    
1609dupA                         Duplication of adenine in position 1609 
A                                       Alanine (Ala)  
A1, A2a, A2b, A3                      Adenosine receptor A1, A2a, A2b, A3    
ABC                                  ATP-binding cassette 
ABCB                               ATP-binding cassette, sub-family B  
ABCC                               ATP-binding cassette, sub-family C   
ABCC6                             ATP-binding cassette, sub-family C,    
                                          member 6 
ABCC6-Flag-pcDNA        Flag-pcDNA containing the sequence coding            
                                          for ABCC6 
ABCC6-Ѱ                          Pseudogene of ABCC6 
ABCC6 Δ19Δ24                 ABCC6 mRNA without exons 19 and 24 







                                          of CD73 
ADP                                  Adenosine diphosphate 
AMP                                 Adenosine monophosphate 
AOPCP                             α,β-methyleneadenosine-5’-diphosphate 
APS                                   Persulfate ammonium 
ATCC                               American Type Culture Collection 
ATP                                   Adenosine triphosphate 
BCRP                                Breast cancer resistance protein 
BLAST                             Basic Local Alignment Search Tool 
BMP-2                              Bone morphogenetic protein-2 
bp                                      Base pairs 
BSA                                  Bovine serum albumin 
C                                       Cysteine (Cys) 
Calcein-AM                      Calcein-acetoxymethyl ester 
CALJA                             Calcification of joints and arteries 
cAMP                               Cyclic adenosine monophosphate 







CD73L                              Long CD73 isoform 
CD73S                              Short CD73 isoform 
CDKs                                Cyclin-dependent kinases 
cDNA                                Complementary DNA 
CFTR                                Cystic fibrosis transmembrane conductance                 
                                          regulator 
cGMP                                Cyclic guanosine monophosphate 
Co2+                                   Cobalt ion 
CSCs                                 Cancer stem cells 
Ct                                      Threshold cycle 
D                                       Aspartic acid (Asp) 
DCF                                  Dichlorofluorescein 
DCFH                               Dichlorodihydrofluorescein 
DCFH-DA                        2’,7’-dichlorofluorescein diacetate 
DMEM                             Dulbecco’s Modified Eagle’s Medium 
DMSO                              Dimethyl sulfoxide 







dNTP                                Deoxynucleotide 
E                                       Glutamic acid (Glu) 
ECM                                 Extracellular matrix 
EDTA                               Ethylenediaminetetraacetic acid 
em.                                    Emission wavelength 
ENPP1                              Ecto-nucleotide pyrophosphate/   
                                          phosphodiesterase type I                                                             
ex.                                     Excitation wavelength 
EX23_29del                      Alu-mediated deletion from exon 23 to exon  
                                          29 
FBS                                   Fetal bovine serum 
Fetuin A                            Alpha 2-Heremans-Schmid glycoprotein 
Flag                                   DYKDDDDK tag 
Flag-pcDNA                     pcDNA vector that codifies for Flag tag 
G                                       Glycine (Gly) 
G418                                 Geneticin 







GBM                                 Glioblastoma multiform 
Gi/o                                                       G protein with α inhibitory subunit 
GPI                                    Glycosylphosphatidylinositol 
Gs                                                        G protein with α stimulating subunit 
HCC                                  Hepatocellular carcinoma 
HEK293                            Human embryonic kidney cells 293  
HepG2                               Human hepatocellular carcinoma cells   
HNF4                                Hepatocyte nuclear factor 4 
HSCs                                 Hemapoietic stem cells 
HuH-7                               Human hepatocellular carcinoma well    
                                          differentiated cells 
K                                       Lysine (Lys) 
kb                                      Kilobases 
kDa                                   Kilodalton 
Ki                                                          Inhibition constant 
L                                        Leucine (Leu) 








MDA-MB-231                  Triple-negative human breast cancer poorly   
                                          differentiated cells 
MDR                                 Multidrug resistance 
Mg2+                                  Magnesium ion 
MGP                                 Matrix gla protein 
mRNA                              Messenger RNA 
MRP                                 Multidrug-resistance associated protein 
MRP6                               Multidrug-resistance associated protein, 
                                          member 6 
MTT                                  3-(4,5-dimethylthiazol-2-yl)-2,5-   
                                          diphenyltetrazolim bromide 
NBD                                  Nucleotide-binding domain 
NCBI                                 National Center for Biotechnology  
                                          Information 
NK-cells                            Natural killer-cells 







NT5E-1                             Long transcript of ecto-5’-nucleotidase 
NT5E-2                             Short transcript of ecto-5’-nucleotidase 
OC                                     Osteocalcin 
OMIM                               Online Mendelian Inheritance in Man 
OPN                                  Osteopontin 
p/q                                     Short/long arm of a chromosome 
p                                        p-value 
PBS                                   Phosphate buffered saline 
PBS-T                               PBS with 0.05% of Tween-20 
PCR                                   Polymerase chain reaction 
PGE2                                 Prostaglandin E2 
P-gp                                   P-glycoprotein 
Pi                                       Phosphate 
PPi                                     Pyrophosphate 
Primer for                          Primer forward 
Primer rev                         Primer reverse 







PXE                                   Pseudoxhantoma Elasticum 
Q                                       Glutamine (Gln) 
R                                       Arginine (Arg) 
RNA                                 Ribonucleic acid 
ROS   Reactive oxygen species 
rpm                                   Revolutions for minute 
S                                        Serine (Ser) 
SD                                     Standard deviation 
SDS                                   Sodium dodecyl sulfate 
SDS-PAGE                       Sodium dodecyl sulfate - polyacrylamide  
                                          gel electrophoresis   
siRNA                               Small interfering RNA 
SO4
-.                                  Sulfate radical 
SUR                                  Sulfonylurea receptor 
 
T                                        Threonine (Thr) 
TBS                                   Tris buffered saline 







TGF-β                               Transforming growth factor-β 
Tm                                    Melting temperature 
TM                                    Transmembrane  
TMD                                 Transmembrane domain 
TNAP                                Tissue non-specific alkaline phosphatase 
TNF-α                               Tumor necrosis factor-α 
U                                       Units 
 
URG7   Up-regulated gene 7 
Y                                       Tyrosine (Tyr) 
Zn2+                                   Zinc ion 
ΔCt                                    Difference between Ct of target gene and Ct    
                                          of housekeeping gene 
ΔΔCt                                 Difference between ΔCt of a target gene in a   
                                          sample and ΔCt of the same gene in the  














Abbreviations: ................................................................................... 7 
Index: ............................................................................................... 17 
Abstract: .......................................................................................... 21 
Introduction: ................................................................................... 23 
1.1 ABC transporters ......................................................................... 24 
1.2 Human ABC transporters ............................................................. 28 
1.3 ABCC subfamily ......................................................................... 33 
1.4 ABCC6 gene and MRP6 protein ................................................... 35 
1.5 NT5E gene and CD73 protein ...................................................... 39 
1.6 Ectopic mineralization ................................................................. 45 
1.7 Pseudoxanthoma Elasticum (PXE)............................................... 49 
1.8 Arterial calcification due to CD73 deficiency (ACDC) and 
generalized arterial calcification of infancy (GACI)……………….... 54 
1.9 Probenecid ................................................................................... 57 
Aims: ................................................................................................ 59 
Materials and Methods: .................................................................. 61 
2.1 Mammalian cellular culture ......................................................... 62 
2.2 Treatment with Probenecid .......................................................... 64 
2.3 Treatment with adenosine ............................................................ 65 
2.4 Treatment with ATP .................................................................... 66 
2.5 Treatment with Quercetin ............................................................ 67 
2.6 Treatment with Doxorubicin ........................................................ 67 







2.8 Doxorubicin efflux assay ............................................................. 70 
2.9 Viability assay ............................................................................. 71 
2.10 Measurement of intracellular Reactive Oxygen Species (ROS) .. 72 
2.11 Calcein assay ............................................................................. 74 
2.12 RNA extraction from cellular lines ............................................ 75 
2.13 cDNA synthesis (RT-PCR) ........................................................ 78 
2.14 Primers design for Real-Time PCR ............................................ 79 
2.15 Real-Time PCR ......................................................................... 80 
2.16 Western blotting ........................................................................ 86 
2.17 Migration assay ......................................................................... 90 
2.18 Cellular cycle analysis ............................................................... 91 
2.19 Imaging assay using confocal microscopy ................................. 92 
2.20 Statistical analysis ..................................................................... 93 
Results and Discussion: ................................................................... 95 
3.1 Inhibition of ABCC6 activity by Probenecid in HEK293 cells ..... 96 
3.2 Effects of Probenecid in HepG2 cells ........................................... 98 
3.2.1 Evaluation of cytotoxicity and morphology........................ 98 
3.2.2 Evaluation of intracellular ROS ....................................... 100 
3.2.3 Evaluation of inhibition of calcein transport ..................... 101 
3.2.4 Evaluation of cellular density ........................................... 102 
3.2.5 Effects of treatment with Probenecid for 24 hours ............ 104 
3.2.6 Effects of treatment with Probenecid for 48 hours ............ 105 
3.2.7 Effects of adenosine and ATP on the modulation                  
of ABCC6 and CD73 expression .............................................. 110 







3.2.9 Evaluation of the mechanism promoting the decrease of  
HepG2 cells migration rate ....................................................... 117 
3.3 Effects of Quercetin and Doxorubicin in HepG2 cells ................ 123 
3.3.1 Effects of Quercetin ......................................................... 123 
3.3.2 Effects of Doxorubicin..................................................... 126 
3.4 Effects of Probenecid in other cellular lines ............................... 128 
3.4.1 Effects of Probenecid in HuH-7 cells ............................... 128 
3.4.2 Effects of Probenecid in MDA-MB-231 cells .................. 135 
3.4.3 Effects of Probenecid in HEK293 cells ............................ 142 
Conclusions and future perspectives: ........................................... 147 
Bibliography: ................................................................................. 153 
Published Papers: .......................................................................... 177 
Other communications: ................................................................. 179 












ABC (ATP-binding cassette) transporters are the largest superfamily  
of membrane proteins present in all organisms and they are particularly 
involved in transport of nutrients and drugs. Among these transporters 
we find ABCC6, belonging to sub-family C, which is an                 
ATP-dependent transporter mainly present in the basolateral plasma 
membrane of hepatic and kidney cells. Mutations in the ABCC6 gene 
are associated to the Pseudoxanthoma Elasticum (PXE), an autosomal 
recessive disease characterized by progressive ectopic mineralization 
processes at level of the skin, the retina and the vascular wall. It has 
been reported that PXE is caused in peripheral tissues by decreased 
levels of PPi, a strong inhibitor of mineralization processes. In fact,     
the administration of PPi reducing the effects of PXE is considered an 
efficient drug. It is known that the over-expression of ABCC6              
in HEK293 cells results in the outflow of ATP and that is converted 
into AMP and PPi by ENPP1 protein. Then, AMP is transformed into 
adenosine and Pi by CD73 protein; so ABCC6 protein could be 
involved both in providing extracellular adenosine and in the regulation 
of the purinergic system. Previous studies show that in ABCC6-silenced 
HepG2 cells there is a dysregulation of some genes involved in the 
mineralization processes. We performed experiments in order to 
evaluate the mechanism by which ABCC6 is able to promote this genic 
dysregulation. For this purpose, the ABCC6 transport activity           







results obtained in HepG2 cells are partially similar to those ones 
obtained in ABCC6-silenced HepG2 cells. The greatest effects were 
obtained on NT5E and on ABCC6. As an inhibitor, probenecid was 
used to reduce the transport activity of ABCC6 into HEK293 cells.      
In order to confirm that the observed effect is closely related to the 
inhibition of ATP transport, and not to the presence of probenecid, the 
HepG2 cells were also treated with adenosine and ATP. The results 
show that in the presence of 10 and 100 µM of adenosine or 50 and  
500 µM of ATP, the effects of probenecid are reversed. In order to 
confirm the effects of probenecid on the transport activity in these cells 
was tested the quercetin, another ABC inhibitor; the data confirm those 
ones previously obtained with probenecid on the expression of ABCC6 
and NT5E. In HepG2 cells treated with doxorubicin, whose presence 
increases the expression of ABCC6, we observed a proportional 
increase of NT5E. Experiments with probenecid, adenosine and ATP 
were also performed in cells expressing ABCC6 at different levels. The 
results show that in the presence of probenecid in MDA-MB-231 cells 
there is no effect while in the HEK293 and HuH-7 cells there are poor 
effects. The effect of probenecid is obtained only in cells that         
over-express ABCC6; in all these cells, the addition of adenosine and 
ATP improves the expression of CD73. It was also analysed the 
cellular phenotype after the treatment with probenecid. Considering the 
role of CD73 in cellular migration processes, motility assays confirmed       

























1.1 ABC transporters 
Membrane transporters constitute a significant fraction of all proteins 
encoded in the genome of simple and complex organisms. They are 
divided into channels and carriers, two very large classes of proteins, 
within which there are superfamilies defined by both particular 
sequences of amino acids and specific secondary structures.               
The transporters bind their substrates with high stereo-specificity; 
among them there are passive transporters (which transport substrates 
according to a concentration gradient) and active transporters (which 
transport substrates through the membranes against concentration 
gradient). Some of these active transporters exploit the supplied energy 
by a chemical reaction, other of them by coupling the gradient versus 
transport with the gradient transport of another substrates. Among these 
active transporters, which perform their function using the energy 
deriving from the hydrolysis of ATP, one of the most important 
families is ABC (ATP-binding cassette) transporters. ABC transporters 
are the largest superfamily of membrane proteins [1] present in all 
living beings, from microbes to plants and animals [2-4]; they are able 
to couple the transport of a substrate across the membranes to the 
hydrolysis of the phosphate bond between the γ- and the β-phosphate of 
ATP [5-7]; they are codified by ABC genes that are highly conserved 
among species [8]. ABC transporters can work as either importers or 
exporters [9], and are involved in nutrient uptake, in transport of drugs, 







ion and lipid homeostasis, antibiotic and multidrug resistance; for these 
reasons they are the main candidates for cellular regulation and 
pharmacological intervention [11-14]. The proteins of this group are 
mainly classified according to the sequence and organization of their 
cytoplasmic nucleotide-binding domains (NBDs) [15]. All ABC 
transporters show a common basic organization; their functional core 
consists of two NBDs and two transmembrane domains (TMDs)     
(Fig. 1.1).  
 
Fig. 1.1: Basic organization of ABC transporter with two NBDs (red) and two TMDs 
(blue) [8]. 
The TMDs domains are constituted by 6-11 transmembrane α-helicals 
that form a cavity within the membrane through which the substrate   
can be transported. The low sequence similarity among these 
transmembrane domains of the various ABC proteins reflects the wide 
variety of substrates carried [16-18]. The NBDs domains, cytoplasmic 
domains, that bind and hydrolyze ATP, need magnesium (Mg2+) for 
their activity; they are formed by 200-300 amino acids and contain the 
following motifs: A-loop involved in ATP positioning; Walker A, 







binding; Walker B, ɸɸɸɸD (where ɸ is an hydrophobic amino acid 
residue), involved in coordination of Mg2+; D-loop, H-loop, Q-loop the 
main sites of interaction with TMDs, and the signature C motif 
(LSGGQ) located upstream of the Walker B and implicated in binding 
and hydrolysis of Mg2+-ATP [6] [15-16] [19] (Fig. 1.2). 
 
Fig. 1.2: General representation of the functional organization of the ABC proteins: 
A) ABC “full transporters” with 12 TM regions, divided into 2 TMDs, each with an 
NBD domain; B) ABC transporters with 5 extra TM regions, which form the TMD0 
at the N-terminal; C) ABC “half-transporters” with 6 TM regions (one TMD)  and 







Prokaryotic transporters are located in plasma membrane and hydrolyze 
ATP in the cytoplasm, whereas eukaryotic ABC transporters are 
present both in plasma membrane and in organelle membranes and 
hydrolyze ATP in the cytoplasm (except for mitochondria and 
chloroplasts transporters). Eukaryotic ABC transporters can either be 
encoded as a single protein (“full transporters”) or can be considered as 
a result of homo- or hetero-dimerization (“half-transporters”) with only 
one TMD and one NBD [8] (see Fig. 1.2). Moreover, some ABC 
transporters contain an extension to the N-terminal consisting of five  
α-helicals that form the TMD0 domain [18] [21] (see Fig. 1.2).          
The transport mechanism of these proteins is based on the 
conformational change of the TMD domains, induced by the binding of 
the ATP to the NBD sites, which determines the opening to the outside 
and the release of the substrates. After the hydrolysis of the ATP the 
dimer NBD is deactivated and the conformation of the transporter 
returns to its original, facing inward, which represents the orientation 








Fig. 1.3: Transport mechanism of ABC proteins [21]. 
In literature there are structural studies of bacterial ABC transporters; 
for eukaryotic ABC transporters there are no high resolution structures 
[17], but some medium resolution structures, such as P-glycoprotein  
(P-gp) [17] [22]. 
 
1.2 Human ABC transporters  
Human ABC proteins are encoded by 48 genes [23-24], and have been 
classified into seven subfamilies from ABC-A to ABC-G based on the 
similarity in the gene structure, order of the domains, and sequence 







expressed ubiquitously in non-tumor cells or in a tissue-specific manner 
and play a role in metabolic and/or detoxification processes [1].           
In tissues there is a different distribution of ABC proteins and the         
sub-cellular localization of these proteins can be a discriminating 
feature [26]; moreover, the ABC transporters are highly expressed       
in many tumor cells, for example in leukemic and in breast cancer cells 
[26]. In Table 1.1 we can find a list of all human ABC genes known 
with their chromosomal location, their subfamily, their expression 
pattern and their function (if it is known) [8]. 
 
 







Mutations of ABC genes are involved in several and various human 
inherited disorders (Table 1.2) including cystic fibrosis, 
Pseudoxanthoma Elasticum (PXE), tangier disease, alteration in 
metabolism and drug response [6] [25] [27]. 
 







Moreover, the high expression of some ABC proteins in hematopoietic 
stem cells (HSCs) and in cancer stem cells (CSCs), compared to their 
more differentiated counterpart, could suggest the hypothesis that these 
proteins play a role in cellular differentiation [28]. Some ABC 
transporters are involved in the transport of xenobiotics and drugs 
(Table 1.3), and in particular the two subfamilies mainly involved in 
the development of the drug resistance are the subfamily B (known as 
MDR, Multi-Drug Resistance) and the subfamily C (known as MRP, 
Multi-drug Resistance-associated Proteins) [20]. The most important 
and pharmacologically investigated protein is ABCB1 (known as P-gp 
or MDR1), for its implications in drug resistance; the tumor cells that 
over-express this protein show MDR phenotype, and are resistant to the 
















1.3 ABCC subfamily 
The “C” subfamily of these transporters is one of the largest ABC 
subfamilies [15]. Its proteins are full transporters with various 
functions, such as ion transport, toxin secretion [8], and in particular 
drugs resistance (multidrug resistance-associated proteins (MRPs))  
[31-32]. In this subfamily there are 12 members divided into three 
classes: the first one involved in regulation of potassium channels 
(ABCC8 and ABCC9, called SURs, sulfonylurea receptors), the second 
one involved in chloride ion channel (cystic fibrosis transmembrane 
conductance regulator (CFTR)), and the third one, with the other nine 
members, involved in drugs resistance (MRPs) [8] [32-35]. ABCC13, 
the thirteenth member of this family is a truncated protein that encodes 
a non-functional protein [19] [36]. Proteins codified by ABCC genes  
are divided into two groups: “long” transporters including MRP1, 
MRP2, MRP3, MRP6, MRP7, SUR1 and SUR2, and “short” 
transporters including MRP4, MRP5, MRP8, CFTR and probably 
MRP9; the difference between the two groups is the presence in “long” 
transporters of an extra NH2-terminal TMD named as TMD0 and 
connected to the rest of the protein through a cytoplasmic loop 
indicated as L0 or as code CL3 (cytoplasmic loop 3) [37-41], with five 
TMs and an extracellular N-terminus [15]. In “short” transporters there 








Fig. 1.4: Membrane topology of MRP proteins [43]. 
TMD0 sequence is poorly conserved compared to the other two 
homologous TMDs, but the N-terminal region of L0 is relatively 
conserved both in ABCC “long” proteins and in ABCC “short” proteins 
[10] [44]. L0 is predicted to contain two amphipathic α-helicals in all 







of a TMD0 domain in the “long” ABCC transporters is unique and its 
eventual general function has to be clearly established [39].               
For example, TMD0 of MRP1 does not play a crucial role either in 
transport activity of the protein, or in its proper routing into the 
basolateral membrane compartment, while the presence of L0 and of 
other domains is necessary for MRP1 transport activity and for the 
proper intracellular routing of this protein [39] [46]. Moreover, in this 
transporter the L0 region forms a distinct structural and functional 
domain, which interacts with the membrane and with the core region of 
the transporter [39]. TMD0 domain is important for trafficking and 
stabilization of MRP2 in the apical membrane [47], and for the activity 
of SURs [38] [48-49]; L0 is essential for the localization of MPR2 [45] 
and for the regulation of trafficking of SURs [49]. 
 
1.4 ABCC6 gene and MRP6 protein 
The human  ABCC6 gene belongs to the large ABCC subfamily and       
is mapped on chromosome 16 in position p13.1 [50], between its two 
almost identical pseudogenes [51]. ABCC6 gene is immediately near to 
ABCC1 (that codifies MRP1 protein), but these gene are in opposite 
orientation, and the 3’ ends are only 9 kb apart [19] [35] (Fig. 1.5). 
ABCC6 gene spans about 73 kb of genomic DNA [52], its mRNA 







(equal to the number of exons of ABCC1) [35] [53] that codify for the 






Fig. 1.5: Position of ABCC6 gene on chromosome 16 (A). The region of chromosome 
16 containing the ABCC1 and ABCC6 genes (B) [43]. 
There is a splicing variant of ABCC6 mRNA without exons 19 and 24 
(ABCC6 Δ19Δ24), and, the product of the translation is a truncated 
protein that is suggested to be a half transporter [54]. ABCC6 gene has 
about 45% of homology with the ABCC1 gene [35] [55].                 
From mutational analysis, they have been found sequence variants of 
ABCC6 gene deriving from duplication of the p13.1 region of the 
chromosome 16; these variants are ABCC6 pseudogenes [56].           
Two pseudogenes were found in the chromosome 16, ABCC6-Ѱ1 and 
ABCC6-Ѱ2, at the terminal 5’ of the ABCC6 gene [56]. In particular,     
a polypeptide with 99 amino acids indicated as up-regulated gene 7 
(URG7) [57] shows a  high homology with the protein codified by 
ABCC6-Ѱ2 [58]. This protein, URG7, has the first 74 amino acids         









similar because there is high degree of homology between ABCC6 
promoter and 5’UTR of ABCC6-Ѱ2 [58]. Expression tissue-specific of 
ABCC6 gene is finely regulated by the presence on its promoter of 
sequences that bind specific transcription factors such as hepatocyte 
nuclear factor 4 (HNF4) [59] and tumor necrosis factor-α (TNF-α) 
which up-regulate and down-regulate, respectively, the promoter [60]. 
The protein MRP6 is codified by the ABCC6 gene, as reported before, 
and has 1503 amino acids and a molecular weight of about 165 kDa 
[35] [60-61]. MRP6 is a “long” MRP transporter and it is formed by 17 
TMs (grouped in three TMDs) and two cytoplasmic NBDs 
[TMD0(TMD-NBD)2] [62-63] (Fig. 1.4), with conserved Walker A, 
Walker B and motif C [52]. It is mainly expressed in liver and kidney, 
in particular on the basolateral surface of hepatocytes [41] [64-67] and 
poorly expressed in salivary glands, in colon, in lungs and in the thyroid 
[35]. It is also expressed in acute myeloid leukemia [68]. Two possible 
functional models for transport of molecules through ABC transporters 
in general were proposed: the first one suggests that each NBD 
hydrolyzes an ATP molecule and that this reaction promotes the 
transport of a molecule of substrate [19]; the second one suggests that 
hydrolysis of an ATP molecule promote the substrate transport through 
the shift from a high- to low-affinity substrate binding state and 
hydrolysis of the other ATP molecule restores the high affinity substrate 








Figure 1.6: Three-dimensional model of MRP6: (A) nucleotide saturated 
conformational state and (B) nucleotide-free conformation. Missense mutations are 
indicated in red (modified from [59]). 
 
In vitro experiments on chemically synthesized peptide E748-A785 
(that correspond to a part of NBD1) [69], on NBD1 [70] and NBD2 
[71] produced in Escherichia coli by recombinant DNA technologies 
show the ability of these fragments in ATP binding. In particular, 
studies on NBD1 (D627-L851) show that the A- loop of this domain    
is important for affinity to ATP, while, NBD2 of MRP6 (T1252-V1503)  
is structured in order to bind and hydrolyze ATP with a lower efficiency 







MRP6 show that this transporter is associated with ATP-dependent 
transport of glutathione S-conjugates; the transport of conjugates is a 
feature of MRPs that have the third TMD. MRP6 is also associated to 
low level of resistance to agents such as doxorubicin and teniposide 
[15] [19] [23] [72-73]: its natural substrate is not defined [74], and 
MRP6 transport is inhibited by organic anions such as probenecid [75]. 
Finally, the MRP6 is associated to the metabolism of vitamin K [59], 
and, recent studies in HepG2 cells show that low levels of expression of 
MRP6 induce a dysregulation of expression of some genes and a 
senescent-like phenotype (cellular cycle alteration) [76-77]. 
 
1.5 NT5E gene and CD73 protein 
The human NT5E gene is situated on chromosome 6 in position q14-q21 
[78]; this gene spans 46 kb of genomic DNA, and  it has a coding 
sequence of 1725 bp and is made of 9 exons that codify for CD73 
protein [78-79]. Two transcripts of this gene have been identified as 
NT5E-1 (3548 bp) and NT5E-2 (3384 bp), and obtained by alternative 
splicing. The NT5E-2 is a new splicing variant of NT5E gene expressed 
less than NT5E-1 in normal tissues of human body but up-regulated in 
some pathological contexts such as in cirrhosis and in hepatocellular 
carcinoma (HCC) [79]. The difference between the two transcripts is 







shorter transcript (NT5E-2); the two transcripts have the same N- and 
C- terminal [79] (Fig. 1.7). 
 
Fig. 1.7: Transcripts of NT5E gene: NT5E-1 and  NT5E-2. The black arrow indicates 
the position of exon 7 [79]. 
In literature is reported that the expression of this gene is under the 
control of hypoxic conditions [80-81] and of several pro-inflammatory 
mediators such as transforming growth factor-β (TGF-β) or 
prostaglandin E2 (PGE2) [82-83]. It has also been reported that the 
increase of NT5E transcript, and of its correspondent CD73 protein in 
neoplastic tissues can play a key role in the onset and progression of 
neoplasia [82]. There is also a similar positive correlation between 
triple-negative breast cancer and NT5E levels associated to a poor 
prognosis [84]. The protein CD73, cluster of differentiation 73,             
is codified by the NT5E gene, as reported before, and has 574 amino 
acids and a molecular weight of about 70 kDa. NT5E-1 encodes for 
CD73 long isoform (CD73L, 574 amino acids), the enzymatically 
active isoform, while, NT5E-2 encodes for CD73 short isoform 







The mature CD73 form  is a glycosylated dimeric enzyme located on 
the outer portion of the plasma membrane [85-87], and it is present in 
different organs (such as colon, kidney, liver, heart [88-89]) and cells 
(such as lymphocytes, macrophages and epithelial cells [88]).          
This protein is anchored to the external face of plasma membrane 
through glycosylphosphatidylinositol (GPI) situated on C-terminal [86] 
[90-91], and, consists of two protein subunits united through           
non-covalent links. N-terminal domain coordinates the link of two 
divalent metal ions (Zn2+ and Co2+) and is characterized by α/β-β-α-β 
secondary structure. C-terminal domain provides the linking pocket for 
AMP [91],  and has a sequence of non-charged and hydrophobic amino 
acids substituted with the GPI anchor linked to serine-523 [92].        
The active site of the enzyme is located at the interface between the    
N- and C-terminal domains and shape among the residuals of both 
domains. Have been described different crystalline structures for CD73: 
if the conformation of CD73 is open it is characterized by a rather 
compact structure, if the conformation is closed it is characterized by a 








Fig. 1.8: Crystalline structure of CD73 in open and closed conformations [90]. 
The two isoforms show different functions: CD73L is the isoform 
enzymatically active, an ecto-5’-nucleotidase, able to catalyze the 
conversion of extracellular AMP, produced by ENPP1 protein, to 
adenosine and Pi [85]; CD73S is the isoform catalytically inactive, 
unable to dimerize, but able to link both with the calnexin and with 
CD73L promoting proteasome-dependent CD73L degradation [79].  
For its role in the production of extracellular adenosine CD73            
can be considered a fundamental actor in the regulation of immunity 
response and in other pathways (for example: inflammation, ischemia, 
tissue fibrosis [93]). CD73-adenosine pathway is an important 
immunosuppressive pathway and this property is linked to its ability of 







The adenosine is a strong immune-suppressor, in particular, of 
antitumor T-cells response [95]. Increasing evidence shows that CD73 
participates in tumor immune-escape by inhibiting the activation, clonal 
expansion, and homing of tumor-specific T cells [96]; the adenosine 
decreases the ability of natural killer cells (NK-cells) to produce     
TNF-α, to promote lytic activity [97], and to decrease the activity of 
macrophages [98] and dendritic cells [99-100] (Fig. 1.9). 
 
Fig. 1.9: The effects of adenosine (produced in cancer cells by CD73) on immunity 







Furthermore, CD73 is involved in drug resistance [102], in tumor 
growth [103], tumor metastasis (through binding to glycoproteins of the 
extracellular matrix (ECM), such as fibronectin and laminin) [104-106] 
and tumor angiogenesis [107]. In particular, recent studies show that in 
some types of cancer CD73 could promote the migration and invasion 
of cancer cells through regulation of EGFR expression, in others type 
of cancer, it could be an important regulator of epithelial-mesenchymal 
transition [99]. Different strategies are studied to control this protein 
using inhibitors, such as AOPCP, α,β-methyleneadenosine-5’-
diphosphate, or using antibodies. CD73 is related to the metabolism of 
nucleotides and nucleosides (cellular messengers), and it can control 
different cellular processes in purinergic system. The purinergic system 
is a system deputed to cellular proliferation and transformation, cellular 
cycle progression, metabolic changes, cell-to-cell interactions, cytokine 
and chemokine secretion, inhibition of lipolysis, promotion of fatty 
liver insulin resistance, intracellular pathogen removal and generation 
of reactive oxygen species (ROS) [108]. Extracellular adenosine 
regulates a variety of physiological processes (previously mentioned) 
using a family of four receptors related to G-protein (A1, A2a, A2b, A3) 
each of which is characterized by a single pharmacological profile and 
tissue distribution. A1, A2a and A2b protein sequences are highly 
conserved across mammalian species, while, A3 is more variable.         
In human, A1, A2a and A3 are considered as high affinity receptors for 
adenosine (Ki about 100-300 nM), while A2b receptor has a lower 







show a structure with seven transmembrane α-helicals, with an 
extracellular N-terminus and an intracellular C-terminus. Finally, these 
receptors perform their specific functions in different tissues because 
they regulate the cAMP levels differently (in particular, A1 and A3 
receptors are coupled to inhibitory Gi/o proteins, while, A2a and A2b 
receptors are coupled with to stimulating Gs proteins [111]). 
 
1.6 Ectopic mineralization 
The physiological process that provides for the formation of bone 
matrix and the functionality of skeletal tissue is known as 
mineralization (or calcification). This phenomenon, which is tightly 
controlled and restricted to specific body regions [51], can also occur in 
soft tissues and it is known as ectopic mineralization. This type of 
pathological calcification occurs when calcium and phosphate 
complexes form hydroxyapatite crystals and they settle in the soft 
tissues causing serious consequences at the clinical level. Moreover, 
this complex multifactorial metabolic process is associated with 
different clinical conditions such as aging and diabetes [112]. There 
have been many advances in the study of ectopic mineralization 
processes both in terms of molecular mechanisms and of single gene 
disorders characterized by phenotypic traits typical of calcification 







ectopic mineralization (Table 1.4). In particular, Pseudoxantoma 
Elasticum (PXE) and Arterial calcification due to CD73 deficiency 
(ACDC) are related to ABCC6 and NT5E gene mutations [112]. 
 
Table 1.4: Diseases characterized by ectopic mineralization [112]. 
Calcium and phosphate precipitation is highly regulated by calcification 
inducers and inhibitors [113-114]. In particular, inorganic 
pyrophosphate (PPi) [115] acts as a powerful inhibitor of 
mineralization; phosphate (Pi) is a pro-mineralization factor, and an 







mineralization under homeostatic conditions [112] [116]. Alterations of 
the metabolic pathway of extracellular ATP can be considered among 
the main causes of the manifestation of these pathological forms of 
mineralization. ATP, a precursor of PPi and Pi, is released by the liver 
cells [115] [117]: its passage in the extracellular environment                
is facilitated by membrane transporters such as ABCC6 (other 
mechanisms are vesicular exocytosis, hemichannel connexion and 
pannexin channel [118]), and, recently, it has been suggested that,        
in pathological conditions, the loss of the ABCC6-dependent outflow   
of ATP would cause an alteration of the extracellular PPi/Pi ratio         
[119-120]. Then, ATP is converted, in the vascular system of the liver, 
into PPi and AMP, by ENPP1 protein, an ecto-nucleotide 
pyrophosphatase/phosphodiesterase 1, encoded by ENPP1 gene [121]. 
AMP is converted into adenosine (an activator of the purinergic 
pathway) and Pi by CD73 [85] [121]. ABCC6 protein is thus involved 
in the production of extracellular adenosine and therefore could be 
involved in the activation of the purinergic pathway; however,           
the mechanism through which ABCC6 dysfunction causes diminished 
ATP release remains an enigma [122]. Finally, PPi is converted in two 
molecules of Pi by TNAP protein, a tissue non-specific alkaline 
phosphatase, encoded by TNAP gene. For its ability to produce Pi, 
TNAP can be considered another important factor that controls the 
mineralization processes [85], while, adenosine is considered an 
inhibitor of TNAP [86]. The reactions above mentioned are well 







have hypothesized that adenosine could control the phenomenon of 
ectopic calcification not only by acting on TNAP expression, but also 
by activating the A2a receptor and consequently the membrane 
translocation of the protein ENPP1, whose expression is crucial in the 
regulation of the processes of mineralization of soft tissues [123]. 
 
Fig. 1.10: Pathway of extracellular ATP [85]. 
 
At the moment, it is not known the mechanism through which ABCC6 
promotes the release of ATP in extracellular space. It is not defined 
whether ABCC6 directly or indirectly transports ATP [119]. Moreover, 







purinergic system, and therefore regulate some fundamental 
physiological processes such as proteic, glucidic, and lipidic 
metabolisms, immunity and mineralization processes [124-126].     
Other important actors of mineralization processes in soft tissues are: 
matrix gla protein (MGP), osteocalcin (OC), osteopontin (OPN),     
bone morphogenetic protein-2 (BMP-2) and alpha 2-Heremans-Schmid 
glycoprotein (Fetuin-A) [113]. In particular, MGP acts through the 
repression of BMP-2 and consequently is an inhibitor of formation of 
calcium crystals [113]. Fetuin-A is an important serum carrier of 
calcium and phosphate and is an inhibitory factor of calcification of 
soft tissues [113]. OPN, an acidic secreted phosphoprotein, is involved 
in blocking hydroxyapatite deposition and promoting crystal resorption 
[127]. 
 
1.7 Pseudoxanthoma Elasticum (PXE) 
Alterations in relationships of factors involved in mineralization of soft 
tissues promote an ectopic mineralization that causes different diseases 
such as Pseudoxanthoma Elasticum (PXE). PXE (OMIM, online 
Mendelian inheritance in man, 264800) is a disease caused by 
mutations of ABCC6 gene. There have been found more than of         
300 mutations in ABCC6 NBD domains such as deletions, insertions or 







is a stop codon), is the most frequent mutation (about 30%); 
EX23_29del deletion is also recurrent (about 10%) in European patients 
suffering from PXE [52] [130-131]. Furthermore, some mutations cause 
truncated forms of the protein and/or ABCC6 incorrect localization. 
 
Fig. 1.11: Schematic representation of ABCC6 protein with the positions related to 







This disease is an autosomal recessive disorder characterized by 
calcified and fragmented elastic fibers at level of the skin (plaques),    
the retina (peau d’orange, retinal angioid streaks, break of Bruch’s 
membrane [129]) and the vascular wall (atherosclerosis, angina 
pectoris) [122] [132-133], as reported in Fig. 1.12.   
 
Fig. 1.12: Typical manifestations of PXE [134]. 
The prevalence of PXE is unknown. It is estimated its presence in about           
1:50,000-1:100,000 people [132] [135], with a slight female 
predominance [136]. This pathology is sometimes underdiagnosed for 
its rarity and for its highly variable phenotype [132]. Heterogeneity 
phenotype of PXE suggests the influence in the development of the 
pathology of different environmental factors such as nutrition [132], 







are no pharmacological care for this pathology. In PXE patients all 
organs of the body show extracellular matrix alterations, but eyes and 
skin are more severely involved independently of the type of mutation 
[131]. Usually the onset of the PXE occurs in late childhood or 
adolescence [59] and clinical manifestations progress with age [131]. 
Among the first manifestations of PXE we can find the appearance of 
yellow-ivory soft papules with a reticular pattern [132] and of plaques 
in the skin causing the lost of elasticity at level of antecubital fossae or 
sides of the neck [52] [129]; later these signs appear at the back of 
knees and at level of oral mucosa and anogenital skin [132]. In PXE 
patients we also find alterations of Fetuin-A, BMP-2 and vitamin K 
[59], but, we don’t find alterations in levels of calcium, phosphate or in 
the inflammation processes [114]. There is no satisfactory correlation 
between genotype and phenotype [137], and diagnosis of PXE comes 
from the individuation of fragmented calcified elastic fibers thanks to a 
skin biopsy using von Kossa staining [59]. The different manifestations 
of PXE were standardized in 2007 and the system that groups them into 
various classes is called Phenodex (PXE phenotype index).               
The molecular mechanism that induces onset of PXE (when ABCC6 is 
not functional) is not clear [138]. The presence of low levels of ABCC6 
protein in tissues of patients suffering from PXE (Fig. 1.13) suggests 
that PXE is a metabolic disorder [139], resulting in the alteration of 








Fig. 1.13: Tissues in which ABCC6 protein is expressed and tissues affected by PXE 
disease [52]. 
It is known that hepatic ATP is excreted with a mechanism related to 
the ABCC6 protein. Reducing the activity of ABCC6 decreases PPi      
at the extracellular level [120]; it was, also, observed an alteration        
of metabolites related to ATP in PXE patients [141]. In PXE        
patients was observed a reduced concentration of vitamin K,       
cofactor of γ-carboxylation, a fundamental reaction activating          







In stable ABCC6-silenced HepG2 cells, we find an increase of                        
pro-mineralization factors and a decrease of anti-mineralization factors: 
TNAP is up-regulated at transcript, protein and activity levels; 
NT5E/CD73 are downregulated at transcript and protein levels;    
Fetuin-A and OPN result down-regulated at transcript level [76].          
On the basis of these information for the treatment of PXE there are 
experimented the following treatments: oral administration of PPi [142], 
oral administration of bisphosphonates, a stable form of PPi [143], oral 
administration of phosphate binders [144], modifiers of protein 
conformation (such as sodium 4-phenylbutyrate) that target the protein 
to the plasma membrane [145]. 
 
1.8 Arterial calcification due to CD73 deficiency 
(ACDC) and generalized arterial calcification of 
infancy (GACI) 
Other important diseases related to ectopic mineralization are arterial 
calcification due to CD73 deficiency (ACDC) and generalized arterial 
calcification of infancy (GACI); these diseases, together with PXE, are 
characterized by similar phenotypic traits, and by alterations                 
of some factors involved in balancing pro-mineralization and                        








Fig. 1.14: Homeostasis of calcification processes depends on the functioning of some 
enzymes. Some diseases caused by altered functions of these proteins are: PXE, 
GACI and ACDC [146]. 
ACDC (OMIM, 211800) is a disease caused by mutations in NT5E 
gene, and it is a rare autosomal recessive disease characterized by the 
calcification of the large arteries of upper and lower limbs and by the 
calcification of coronary circulation [85] [121] [139]. For these clinical 
manifestations ACDC is also known as CALJA (calcification of joints 
and arteries) (OMIM, 211800) [112]. In literature it is related to new 







in patients affected by ACDC are S221X (where X is a stop codon), 
C358Y and a truncated protein caused by 1609dupA [85]. In patients 
affected by ACDC we find a decrease of NT5E gene and a decrease of 
protein and activity of CD73 protein [85], with low levels of adenosine, 
but normal serum levels of calcium, phosphate and vitamin D.          
The reduction of extracellular adenosine, caused by alterations of CD73 
activity, seems to increase the activity of TNAP protein, and, 
consequently, the hydrolysis of PPi increases the ratio between Pi and 
PPi favoring the calcification processes [85-86] [148]. The addition of 
adenosine reverses these effects both in presence of ACDC or in 
presence of PXE fibroblasts [114]. GACI (OMIM, 208000) is an 
autosomal recessive disease caused by mutations of ENPP1 gene,      
that is mapped on chromosome 6 in position q22-q23 [86] [149].          
In patients affected by GACI we find a severe calcification of the 
elastic lamina inside the large and medium-sized arteries producing an 
arterial stenosis and others cardiac diseases [150-151], and a decrease 
of PPi levels [149]. GACI is a rare condition (reported in about 180 
individuals [152-153]) whose prognosis is extremely poor (85% of 
affected infants die within the first six months of life [154]).               
As reported in literature, mutations in ENPP1 gene could be associated 
with a PXE phenotype [155], but also mutations in ABCC6 gene could 
be associated to GACI disease [64] [155]. The formation of PPi as the 
result of the sequential action of ABCC6 and ENPP1 proteins could 
explain the correlation between PXE and GACI, while low levels of PPi 








Probenecid, 4-dipropylsulfamoylbenzoic acid, is a uricosuric drug used 
for the treatment of gout. In gout an excessive presence of uric acid, 
produced by the metabolism of purine nitrogenous bases, could 
promote the precipitation of uric acid in the form of crystals. 
Probenecid is able to increase the excretion of uric acid and block the 
reuptake at kidney level [156]. Probenecid, generally, is administered 
orally; its absorption is rapid and complete and it is metabolised in the 
liver and eliminated by kidneys. The inhibition of the renal tubular 
transporter thanks to probenecid is also clinically exploited to increase 
the effective concentrations of antibiotics, chemotherapeutics, and other 
medications [157]. Side effects can be nausea, vomiting, fatigue and 
skin rash. The block of cAMP or cGMP release from erythrocytes 
[158-159], and, ATP release from glia cells [160] by probenecid show 
its involvement in the efflux of these substrates. For these reasons 
experiments have been carried out to investigate the correlation 
between probenecid and the mechanisms involved in the transport of 
ATP (such as pannexins, connexins and ABC transporters). The results 
of a study, in particular, show that probenecid is a powerful inhibitor of 
pannexin 1 channels, but it has no effects on connexin channels [157]. 
Probenecid is, also, a known ABC transporters inhibitor [157] [161].   
In fact, a study show that probenecid is an effective chemosensitizer for 
MDR cells that overexpress MRPs, and, is a potential candidate for 







probenecid (0.1-0.5 mM) that reversed MRP-mediated MDR are 
readily achievable in vivo [162]. Moreover, ABCC6 transport is 
inhibited by organic anions such as probenecid [75]: 1 mM of 
probenecid, efficiently, inhibits MRP1 and MRP2, but it poorly inhibits 
ABCC6 (about 30%) [75]. Finally, it is also known that CD73 is related 
to MDR proteins, and, its increase in different kinds of tumors [89] 
such as glioblastoma multiform (GBM) [163] and breast cancer    
(where it is over-expressed) promotes a highly aggressive tumor 
phenotype [105]. In literature it is reported that using AOPCP, a CD73 
inhibitor, it is possible to reverse the MDR phenotype in GBM cells 
through the decrease of expression and activity of MRP1 [163];          
for these reasons, it could be possible to control CD73 expression using 








The aim of this scientific research is to study the role of ABCC6 
protein in some fundamental cellular processes. It is known that 
ABCC6 protein is able to transport ATP outside the cells and that 
mutations in ABCC6 gene cause the Pseudoxanthoma Elasticum (PXE) 
a disease characterized by a decrease of the amount of extracellular PPi, 
by the ectopic mineralization processes in some regions of the body and 
by the alteration in releasing of extracellular nucleotides and purine 
nucleosides, with a possible involvement of the activation of purinergic 
system. ATP transported by ABCC6 is catalysed into PPi and AMP by 
ENPP1 protein; AMP is catalysed into Pi and adenosine by CD73 
protein. So we intended to investigate the role of ABCC6 in the 
purinergic system. In this scientific research we want to verify the 
effect of the ATP and of the adenosine, on the expression of ABCC6 
and CD73 protein. In particular, the transport activity of ABCC6 in 
HepG2 cells was blocked by an inhibitor of ABC proteins and the gene 
and protein expression analysis was carried out on NT5E/CD73. Other 
effects related to the low activity of ABCC6, due to this inhibitor, have 
been studied with a particular attention to the role of CD73 in cancer 
progression. Furthermore, similar experiments were performed       
using doxorubicin and quercetin and other cellular types in order to 
highlight the correlation between ABCC6 and CD73. We performed              
some experiments in collaboration with the University of                  































All compounds used for the following scientific research were 
purchased from Sigma-Aldrich (unless otherwise indicated). 
 
2.1 Mammalian cellular culture 
Human embryonic kidney 293 cells (HEK293), human hepatocellular 
carcinoma cells (HepG2), human hepatocellular carcinoma well 
differentiated cells (HuH-7) and triple-negative human breast cancer 
poorly differentiated cells (MDA-MB-231) are the adherent 
mammalian cell lines used for the experiments of my research        
(Fig. 2.1). These cells were grown in Forma STERI-CYLE CO2 
incubator and were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 4.5 g/L glucose, supplemented with 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, penicillin (100 U/mL), 
and streptomycin (100 mg/mL) in polystyrene flasks at 37°C, in an 
atmosphere humidified with 5% of CO2. The cell splitting was obtained 
using Trypsin-EDTA solution (1X) for 5 minutes at 37°C to detach 
cells from flasks; trypsin was inactivated with a double volume of 
complete medium. All cells (except HEK293) were washed with     
PBS 1X, phosphate buffered saline, (140 mM NaCl, 10 mM Na2HPO4,      
2.7 mM KCl and 1.8 mM KH2PO4, pH 7.4) before trypsin treatment. 
All solutions were warmed at 37°C using Water bath SWBD Stuart 
before use. Cells were observed with microscope Nikon Eclipse TS100 






and counted using Burker chamber. The number of cells was calculated 
with the following formula: 
cells/mL = counted cells * dilution factor * 10
4 / number of counted squares 
After counting, an appropriate group of cells was seeded in flasks     
(see next sections). The pellets of non-treated or treated cells were 
obtained transferring opportunely the cells into tubes and centrifuging 
them at 1200 rpm for 5 minutes at 4°C. After elimination of the 
medium, the pellets were immediately used or stored at -80°C.  
 
Fig. 2.1: Representative images of mammalian cellular culture: HEK293 cells (A), 
HepG2 cells (B), HuH-7 cells (C) and MDA-MB-231 cells (D).  
These images are taken from ATCC (American Type Culture Collection). 






2.2 Treatment with Probenecid 
Probenecid is a well-known inhibitor of multidrug resistance-associated 
proteins, MRPs [162] (Fig. 2.2). It was dissolved in dimethyl sulfoxide 
(DMSO) at 30 mg/mL (100 mM) as stock solution and it was then 
diluted with DMEM to the desired concentrations. The final 
concentration of DMSO did not exceed 1% v/v in the MTT viability 
assay and in measurement of intracellular ROS assay; in the other 
experiments the final concentration of DMSO did not exceed 0.25% 
v/v. Control cells were treated at the same final percentage of DMSO.  
6 × 10
5
 HepG2, HuH-7 or HEK293 cells and 2.5 × 105 MDA-MB-231 
cells were seeded in each well of 6-wells plates in 2 mL of DMEM. 
After 24 hours from their seeding, these cells were treated for 24 and 
48 hours with 250 µM of probenecid.   
 










2.3 Treatment with adenosine 
Adenosine is produced primarily from the metabolism of ATP and 
exerts pleiotropic functions throughout the body [164] (Fig. 2.3). It was 
dissolved in dimethyl sulfoxide (DMSO) at 80 mg/mL (300 mM) as 
stock solution and it was then diluted with DMEM to the desired 
concentrations; the percentage of DMSO deriving from adenosine is 
negligible if compared with the amount of DMSO used for probenecid. 
6 × 10
5
 HepG2, HuH-7 or HEK293 cells and 2.5 × 105 MDA-MB-231 
cells were seeded in each well of 6-wells plates in 2 mL of DMEM. 
After 24 hours from their seeding, these cells were treated for 48 hours 
with 10 and 100 µM of adenosine. Other experiments using the cells, 
previously indicated, were performed in presence of both probenecid 
(250 µM) and adenosine (10 and 100 µM) for 48 hours. 
 
Fig. 2.3: Structure of adenosine. 
 






2.4 Treatment with ATP 
ATP, adenosine 5’-triphosphate, a component of energy storage and 
metabolism in vivo, is a substrate involved in cell signaling and in 
production of second messengers (such as cAMP) (Fig. 2.4). It was 
dissolved in PBS 1X at 27.5 mg/mL (50 mM) as stock solution, it was 
adjusted its pH value about neutrality, it was filtered and it was then 
diluted with DMEM to the desired concentrations. 6 × 10
5
 HepG2, 
HuH-7 or HEK293 cells and 2.5 × 105 MDA-MB-231 cells were 
seeded in each well of 6-wells plates in 2 mL of DMEM.                  
After 24 hours from their seeding, these cells were treated for 48 hours 
with 50 and 500 µM of ATP. Other experiments using the cells, 
previously indicated, were performed in presence of both probenecid 
(250 µM) and ATP (50 and 500 µM) for 48 hours.  
 
Fig. 2.4: Structure of ATP. 
 
 






2.5 Treatment with Quercetin  
Quercetin, a flavonoid, is another inhibitor of some multidrug 
resistance-associated proteins, MRPs [165] (Fig. 2.5). It was dissolved 
in dimethyl sulfoxide (DMSO) at 20 mg/mL (66 mM) as stock solution 
and it was then diluted with DMEM to the desired concentrations.        
In all experiments with quercetin, the final concentration of DMSO    
did not exceed 1% v/v. Control cells were treated at the same final 
percentage of DMSO. 6 × 10
5 HepG2 cells were seeded in each well of 
6-wells plates in 2 mL of DMEM. After 24 hours from their seeding, 
these cells were treated for 24 hours with 165 µM of quercetin. 
 
Fig. 2.5: Structure of Quercetin. 
 
2.6 Treatment with Doxorubicin  
Doxorubicin is an anthracycline and is a substrate of ABC proteins [20]  
(Fig. 2.6). It was dissolved in dimethyl sulfoxide (DMSO) at 10 mg/mL 
(17.24 mM) as stock solution and it was diluted with PBS 1X, and, 






then, with DMEM to the desired concentrations. The final 
concentration of DMSO is negligible. Control cells were treated at the 
same final percentage of PBS 1X. The HepG2 cells were seeded in   
T25 flasks at about 50% of confluence in 5 mL of DMEM.              
After 24 hours from their seeding, these cells were treated with 
doxorubicin in the following way: for a week with 10 nM, for a week 
with 20 nM, for a week with 50 nM and then for a week with 100 nM. 
 
Fig. 2.6: Structure of Doxorubicin hydrochloride. 
 
2.7 Stable transfection of ABCC6 in HEK293 cells 
Transfection is the process of introducing exogenous biological 
material (DNA, siRNA) into eukaryotic cells, in particular into 
mammalian cells (Fig. 2.7). This process can be transient if the genetic 
material does not integrate into the host genome, and, it can be stable    
if the genetic material is permanently integrated into the host genome.     
2 × 10
5 HEK293 cells were seeded in each well of 12-wells plates        






in 1 mL of DMEM. After 24 hours from their seeding (50-70% of 
confluence), the medium was changed and it was composed                
the transfection mix with 100 µL of incomplete medium and 3 µL        
of FuGene6 transfection reagent (Promega). This transfection mix     
was maintained for 5 minutes at 25°C and, then, mixed with 1 µg         
of empty Flag-pcDNA vector (pcDNA vector that codifies 
DYKDDDDK Flag tag, as control) or Flag-pcDNA containing 
sequence coding for ABCC6 (ABCC6-Flag-pcDNA vector).             
After 15 minutes at 25°C, this transfection mix was added to cells    
drop by drop. The plates were rotated to distribute the added solution. 
Limiting dilution method was used to select individual clones.            
For 18 days the medium containing geneticin (800 µg/mL, Euroclone) 
was changed twice a week. As the clones grew, they were transferred   
in bigger culture flasks (the biggest once were T25 flasks); then,             
the cells were stored in cryovials or used for the experiments.  
 
Fig. 2.7: Mechanism of transfection. 






2.8 Doxorubicin efflux assay 
It is known in literature that the ABCC6 transporter is also involved in 
transporting different drugs such as doxorubicin [20] (Fig. 2.6). For this 
reason the doxorubicin assay is important to understand the role of this 
transporter in the presence of probenecid, a specific inhibitor of MRPs. 
3 × 10
5 HEK293 stably over-expressing ABCC6 and control cells were 
seeded in each well of 12-wells plates, pre-treated with poly-D-lysine 
hydrobromide for 30 minutes, in 1 mL of DMEM. After 24 hours from 
their seeding, the medium was removed, and 300 µL of PBS 1X       
with 1 mM probenecid or with DMSO (as control) were added.         
The cells were incubated for 1 hour. The following steps were all 
performed in the dark to avoid the loss of fluorescence. Then in each 
well were added 5 µM of doxorubicin and the cells were incubated in 
the dark for 30 minutes at 37°C in 5% of CO2. The cells were washed 
two times with cold PBS 1X and their external fluorescence               
was measured at different times using black 96-wells plates                
and GloMax Multi Detection System (Promega) with a blue filter             
(ex. 490 nm, em. 510-570 nm). 
 






2.9 Viability assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide 
(MTT) assay was used to assess the viability of cells treated              
with different compounds at different concentrations for different times 
of incubation. This is a colorimetric assay based on the conversion       
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide salt,         
a yellow compound, into formazan, a violet compound, that absorbs     
at 570 nm (Fig. 2.8). The formazan produced by this reaction is directly 
proportional to the cell number and to the efficiency of mitochondrial 
enzymes of cells. 1 × 10
4
 HepG2, HuH-7 or HEK293 cells and 8 × 103 
MDA-MB-231 cells were seeded in each well of 96-wells plates in   
100 µL of DMEM. After 24 hours from their seeding, the medium was 
removed and the cells were treated with different concentrations           
of probenecid (250, 500 and 1000 µM) for 24 and 48 hours. Another 
experiment in HepG2 cells was performed in the same conditions, 
above mentioned, but in presence of different concentrations of 
quercetin (165, 330, 660 µM) for 24 and 48 hours. The control cells 
were treated only with vehicle DMSO at the percentage of 1% v/v. 
After the treatment, the medium was removed and the cells were 
incubated with 100 µL of fresh medium containing 15% MTT for          
4 hours at 37°C. The formazan crystals were finally dissolved for          
1 hour at 37°C in 100 µL of a DMSO:isopropanol (1:1) solution with 
1% of Triton X-100. MTT reduction was quantified by measuring      






the light absorbance at 570 nm, with background subtraction at 630 nm, 
and by using a microplate reader MultiskanTM GO Microplate 
Spectrophotometer (Thermo Scientific). Results were proportionally 
compared to the control cells. The cells were, also, observed thanks to a 
phase-contrast microscope and representative fields were photographed 
using a Nikon Coolpix P6000. Each test was repeated three times in 
triplicate.  
 
Fig. 2.8: Reaction of conversion of MTT salt (a yellow compound)  in formazan        
(a violet compound). 
 
2.10 Measurement of intracellular Reactive 
Oxygen Species (ROS) 
The intracellular level of ROS was determined using a cell-permeable 
probe, 2’,7’-dichlorofluorescein diacetate (DCFH-DA). This molecule, 
in the cell, is deacetylated by intracellular esterases and converted to 






the dichlorodihydrofluorescein (DCFH) carboxylate anion, which         
is retained in the cell and oxidized rapidly into a highly fluorescent 
compound dichlorofluorescein (DCF) in the presence of ROS [166]  
(Fig. 2.9). 1 × 10
4
 HepG2 cells were seeded in each well of dark        
96-wells plates in 100 µL of DMEM. After 24 hours from their 
seeding, the medium was removed, and, the cells were treated with 
different concentrations of probenecid (250, 500 and 1000 µM) for 24 
and 48 hours. The control cells were treated only with vehicle DMSO 
at the percentage of 1% v/v. As positive control of ROS presence,      
500 µM of a tert-butyl hydroperoxide solution was used for 1 hour       
(1 hour before the end of treatment), only in control cells. Then, cells 
were treated with 10 µM of DCFH-DA for 30 minutes at 37°C.        
The fluorescence was measured by GloMax Multi Detection System 
(Promega) with a blue filter (ex. 490 nm, em. 510-570 nm).          
Results were proportionally compared to the control cells. 
 
Fig. 2.9: Mechanism of DCFH-DA reaction. 






2.11 Calcein assay 
Calcein-AM is a non-fluorescent, hydrophobic compound that easily 
permeates (for diffusion) in living cells. The hydrolysis of calcein-AM 
by non-specific intracellular esterases [167] produces calcein,               
a hydrophilic, strongly green-fluorescent compound that is retained in 
the cytoplasm of the cells. This compound was insensitive to pH and to 
some cations (Fig. 2.10). It is transported out the cells by MRPs, except  
by P-gp and BCRP [17]. 3 × 10
5
 HepG2 or HuH-7 cells and 1.3 × 105 
MDA-MB-231 cells were seeded in each well of 12-wells plates in        
1 mL of DMEM. After 24 hours from their seeding, the medium was 
removed, and the cells were treated with 400 µL of PBS 1X with      
250 µM of probenecid or with 0.25% of DMSO (as control) for 1 hour.     
Another experiment in HepG2 cells was performed in the same 
conditions, above mentioned, but in presence of 165 µM of quercetin or 
with 0.25% of DMSO (as control). Following steps were all performed 
in the dark to avoid the loss of fluorescence. Then, both the treated and 
untreated cells were incubated with  1 µM of calcein-AM for 1 hour at 
37°C in 5% of CO2. After these treatments, the internal and the external 
fluorescence was measured using a black 96-wells plates and               
by GloMax Multi Detection System (Promega) with a blue filter        
(ex. 490 nm, em. 510-570 nm). The external fluorescence was 
measured taking 100 µL of medium from each well, while, the internal 
fluorescence was measured after lysing; the cells were lysed using 300 






µL of TBS 1X, tris buffered saline, (150 mM NaCl and 10 mM Tris, 
pH 8.0) with 0.25% of SDS and transferred in tubes. After 15 minutes 
on ice, the tubes were centrifuged at 13000 rpm for 10 minutes at 4°C, 
and, the supernatants were used to measure the internal fluorescence   
(as previously described). 
 
Fig. 2.10: Mechanism of Calcein-AM reaction. 
 
2.12 RNA extraction from cellular lines 
RNA was extracted from cellular pellets (6 × 10
5 cells) using        
Quick-RNATM MiniPrep kit (Zymo Research) according to the 
manufacturer’s instructions: 
 300 µL of RNA lysis buffer was added to each sample to 
resuspend and lyse cells; 






 each sample was vortexed and centrifuged at 13000 rpm for      
1 minute using the Microliter centrifuge Z 233 M-2 (Hermle 
Labor Technik GmbH); 
 the supernatant was transferred in Spin-AwayTM Filter (yellow) 
columns placed in collection tubes and centrifuged at 13000 
rpm for 1 minute to eliminate the majority of genomic DNA 
(gDNA); 
 an equal volume of 100% ethanol was added to the flowthrough 
and the mixed sample was transferred in Zymo-SpinTM IIICG 
(green) columns placed in collection tubes;         
 each sample was centrifuged at 13000 rpm for 30 seconds and 
its flowthrough was eliminated: 
 400 µL of RNA wash buffer was added to wash column and it 
was centrifuged at 13000 rpm for 30 seconds; 
 DNase I reaction mix:      64 µL of RNA wash buffer 
                                                 3 µL of DNase/RNase-free water 
                                                 5 µL of DNase I (1 U/µL) 
                                                 8 µL of 10X DNase I reaction buffer 
was then added to each column, incubated for 15 minutes at 25°C 
and centrifuged at 13000 rpm for 30 seconds; 






 each column was firstly washed with 400 µL of RNA prep 
buffer and centrifuged at 13000 rpm for 30 seconds, then with 
700 µL of RNA wash buffer and centrifuged at 13000 rpm for 
30 seconds and at the end with 400 µL of RNA wash buffer and 
centrifuged at 13000 rpm for 2 minutes; 
 after, the ethanol evaporation, 25 µL of DNase/RNase-free 
water was added on each filter of column and, after 1 minute of 
incubation, RNA was eluted centrifuging it at 13000 rpm for 30 
seconds. 
Finally, 2 µL of extracted RNA were placed into µDrop Plate (Thermo 
Scientific) and used to measure its concentration with a MultiskanTM 
GO Microplate Spectrophotometer (Thermo Scientific) and a SkanIt 
Software 3.2 for Multiskan GO (Thermo Scientific). The instrument 
was set to measure the absorbance at three wavelengths 230, 260 and 
280 nm and then to calculate RNA concentration and 260nm/280nm  
and 260nm/230nm ratios. The last two values give us information about 
the purity of RNA sample; values of 2.0 and 2.0-2.2, respectively, 
indicate a good quality of RNA. 
 
 






2.13 cDNA synthesis (RT-PCR) 
After the extraction, RNA was transcribed to cDNA through reverse 
transcription reaction using random primers and High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystem). The mix of reaction is 
composed by: 
RNA (1 µg)                                                               10 µL 
10X RT buffer                                                            2 µL 
dNTP mix (100 mM)                                               0.8 µL 
10X RT random primers                                             2 µL 
Nuclease free water                                                 3.2 µL  
RNase inhibitor (20 U/µL)                                         1 µL 
Multiscribe reverse transcriptase (50 U/µL)              1 µL 
Each sample was put in peqSTAR 96 Universal Thermo Cycler 
(EuroClone) and subjected to the following program: 
25°C for 10 minutes 
37°C for 2 hours 
85°C for 5 minutes 






Finally, 2 µL of cDNA were placed in µDrop Plate (Thermo Scientific) 
and used to measure its concentration using MultiskanTM GO 
Microplate Spectrophotometer (Thermo Scientific) and a SkanIt 
Software 3.2 for Multiskan GO (Thermo Scientific). The instrument 
was set to measure the absorbance at three wavelengths 230, 260 and 
280 nm and then to calculate cDNA concentration, 260nm/280nm and 
260nm/230nm ratios. The last two values give us information about the 
purity of RNA sample; values of 1.8 and 2.0-2.2, respectively, indicate 
a good quality of cDNA. 
 
2.14 Primers design for Real-Time PCR 
The primers to amplify specific regions of mRNAs and to make 
transcriptomics studies were designed starting from nucleotide 
sequences deposited in the National Center for Biotechnology 
Information (NCBI) data base. For the primers design were used the 
following criteria: 
 Melting temperature (Tm) between 55°C and 60°C; 
 Tm difference between forward (for) and reverse (rev) primers 
not higher than 2°C (if possible); 
 Specific primers for the selected transcripts (Basic Local 
Alignment Search Tool (BLAST)); 






 Selected couples of primers that don’t form hairpins, self-dimers 
and hetero-dimers (Olygo Analyzer Tool); 
 Specific designed primers that are able to span to exon-exon 
junctions, eliminating undesirable genomic DNA amplification. 
All primers were purchased from Eurofins MWG Operon (Edersberg, 
DE) except primer sequences for NT5E-1 and NT5E-2 transcripts [79]. 
 
2.15 Real-Time PCR 
Real-Time PCR is a method for analysing and quantifying in real-time 
the amount of DNA amplification. In this reaction there is a fluorescent 
dye binding DNA. In this experiment was used as fluorescent dye 
SYBR green; this dye is an asymmetric cyanine with poor fluorescence, 
that increases after binding to double-stranded DNA (in a non-specific 
way). The specificity of this reaction is determined only by the primers 
used. In order to amplify cDNA via Real-Time PCR, we used iTaqTM 
SYBR® Green Supermix (Bio-Rad) including, in addition to SYBR 
green I, also AmpliTaq Gold DNA polymerase, dNTPs, an appropriate 
buffer and a passive reference ROX, to normalize the fluorescence 
signals due to differences in concentration and volume of each sample. 
 






The mix of reaction is composed by: 
Power SYBR Green PCR master mix                           10 µL 
Nuclease free water                                                      7.8 µL 
Primer forward (10 µM)                                               0.6 µL 
Primer reverse (10 µM)                                                0.6 µL 
cDNA (300 ng/µL)                                                          1 µL 
Each sample was put in MicroAmp® Fast Optical 96-well Reaction 
Plate with Barcode (0.1 mL) (Applied Biosystems) closed with 
MicroAmpTM Optical Adhesive Film (Applied Biosystems); then,       
the plates were inserted in 7500 Fast Real-Time PCR System 
instrument (Applied Biosystems) and 7500 Software v2.3 (Applied 
Biosystems) was used according to the following program: 
95°C for 10 minutes 
95°C for 15 seconds 
60°C for 1 minute 
The steps 2 and 3 were repeated for 40 cycles. The output of the 
instrument is an amplification plot (Fig. 2.11), showing the increase of 
fluorescence as function of the threshold cycle (Ct). In this cycle the 
fluorescence signal reaches the threshold level defined by a line that is 
set automatically by the instrument and is at least 3 times higher than 






the baseline values of standard deviation. As shown in Fig. 2.11,        
the first part of this curve is indicated as baseline and corresponds to 
signals determined by the aspecific fluorescence; the second one is the 
exponential phase in which fluorescence is proportional to initial target 
amount; the third one is the linear phase in which there is no increase in 
fluorescence proportional to initial target amount. 
 
Fig. 2.11: Amplification plot and amplification phases (from qPCR Technical Guide, 
Sigma). 
 
Ct is the numeric output of the instrument and is inversely correlated to 
the amount of template present in the mix of reaction; it is determined 
during the exponential phase, when the amplification is not inhibited by 
reaction-limiting conditions. The amplification was followed by a 
dissociation reaction with the following program: 
 
95°C for 15 seconds 
60°C for 1 minute 






95°C for 30 seconds 
60°C for 15 seconds 
This method allows us to check if the amplification is specific through 
the identification of Tm of amplicons whose temperature depends on 
their nucleotide composition. Each amplicon is considered as a specific 
melting peak in the first derivate plot of fluorescence as function of 
temperature. The artefacts or non-specific amplifications determine,    
in this plot, the presence of other peaks with different Tm [168].      
Finally, another way to evaluate the specificity of amplifications is the 
presence of a single band in the agarose gel electrophoresis analysis.    
In order to analyze the Real-Time PCR data we used the ΔΔCt method    
(if the amplification efficiencies of target genes and housekeeping gene 
are approximately equal) [169]. This method allows us to calculate ΔCt 
as the difference between Ct of target gene and Ct of housekeeping 
gene (such as β-actin) in each sample. The value of ΔCt is inversely 
proportional to the amount of relative gene. Then, ΔΔCt is calculated as 
difference between ΔCt of a target gene in each sample (such as 
treated-cells) and ΔCt of the same gene in the calibrator sample      
(such as untreated-cells).  Finally, 2^(-ΔΔCt), also named Fold Change,   
is the number indicating how many times a gene is expressed in a 
sample considering that 1 is the expression of the gene in the calibrator 
sample. In particular 2^(-ΔΔCt) can be: 
 egual to 1 if we have the same gene expression in the sample 
and in the calibrator; 






 minor to 1 if we have a decrease of gene expression in the 
sample; 
 major to 1 if we have an increase of gene expression in the 
sample. 
Each test was repeated three times in triplicate. For the present 
scientific research, we used the following couples of primers to analyze 
the corresponding transcripts: 
β-ACTIN: 
for: 5’- CCTGGCACCCAGCACAAT -3’ 
rev: 5’- GCCGATCCACACGGAGTACT -3’ 
ABCB1:  
for: 5’- CCTTCAGGGTTTCACATTTGG -3’ 
rev: 5’- ACTCACATCCTGTCTGAGCA -3’ 
ABCC1: 
for: 5’- GCTGATGGAGGCTGACAAGG -3’ 
rev: 5’- GATGCTGAGGAAGGAGATGAAGAG -3’ 
ABCC2: 
For: 5’- CCCTTGTCCTGGAAGATGTT -3’ 
rev: 5’- AGAGCCTTCATCAACCAGG -3’ 
ABCC3: 
for: 5’- CCACACCACAACCACCTTCAC -3’ 
rev: 5’- CTCGGCGTCCAGCACATTG -3’ 
ABCC4: 
for: 5’- GCACACCAGGATTTACATTCAGAG -3’ 
rev: 5’- CCAGACGGACGGCAAACC -3’ 







for: 5’- CCACCATCCACGCCTACAATAAAG -3’ 
rev: 5’- ACAGCCAGCCACCGCATC -3’ 
ABCC6: 
for: 5’- AAGGAACCACCATCAGGAGGAG -3’ 
rev: 5’- ACCAGCGACACAGAGAAGAGG -3’ 
ABCG2: 
for: 5’- ATCACTGATCCTTCCATCTTG -3’ 
rev: 5’- GCTTAGACATCCTTTTCAGG -3’ 
ENPP1: 
for: 5’-CCGTGGACAGAAATGACAGTTTC -3’ 
rev: 5’-ATGGACAGGACTAAGAGGAATTCTAAA -3’ 
NT5E: 
for: 5’- GGGCGGAAGGTTCCTGTAG -3’ 
rev: 5’- GAGGAGCCATCCAGATAGACA -3’ 
p16: 
for: 5’- GTGGACCTGGCTGAGGAG -3’ 
rev: 5’- CAATCGGGGATGTCTGAGGG -3’ 
p21: 
for: 5’- CTGTCTTGTACCCTTGTGCCT -3’ 
rev: 5’- CGTTTGGAGTGGTAGAAATCTGTC -3’ 
p53: 
for: 5’- TGAATGAGGCCTTGGAACTC -3’ 
rev: 5’- ACTTCAGGTGGCTGGAGTG -3’ 
 







for: 5’- TACAAGCACTCCCACTTCATCTG -3’ 
rev: 5’- GCTCGAAGAGACCCAATAGGTAGT -3’ 
 
2.16 Western blotting  
Western blotting analysis allows us to identify one antigen or similar 
antigens by a specific antibody. The cellular pellets were lysed in 
Laemmli sample buffer (60 mM Tris-HCl pH 6.8, 10% glycerol,        
1% β-mercaptoethanol and 0.002% of bromophenol blue) 
supplemented with a cocktail of proteases and phosphatases inhibitors. 
Subsequently, the cellular lysis is accomplished by three thermal 
shocks in order to denature the proteins within the cellular membranes. 
Finally, the samples were incubated at 95°C for 5 minutes in the Digital 
Dry Bath (Labnet) and centrifuged at 4000 rpm for 2 minutes.          
The proteins were resolved on 8%-4% or 15%-4% SDS-PAGE   
(sodium dodecyl sulfate - polyacrylamide gel electrophoresis) gels.               
This electrophoresis technique is helpful to analyse protein samples in a 
three-dimensional matrix, consisting of a polyacrylamide gel immersed 
in running buffer 1X (25 mM Tris, 192 mM Glycine and 0.1% SDS, 
pH 8.3). In order to form these gels we used a mixture of acrylamide 
and bis-acrylamide. When acrylamide polymerizes with other 
monomers and with bis-acrylamide we can observe a formation of 
crosslinks that create a gelatinous matrix with pores of size inversely 






proportional to the amount of polyacrylamide. This polymerization 
reaction starts when N,N,N’,N’-tetramethylethane-1,2-diamine 
(TEMED) catalyses the decomposition of persulfate ammonium (APS) 
in SO4
-. free radical that triggers this reaction. SDS unfolds and charges 
negatively the proteins allowing their migration, in the gelatinous 
matrix, according to their molecular weight in presence of an electric 
field. The proteins with different sizes show different levels of steric 
encumbrance and migrate with different speeds. Gels were obtained 
through the polymerization between two slides separated by two 
spacers. The polyacrylamide gels used were made of two contiguous 
gels: a running gel with a higher amount of polyacrylamide and            
a staking gel in which a comb formed some wells able to load the 
samples.  
The mix for running gel (15%) consisted of: 
Water                                                               2.3 mL 
30% Acrylamide mix                                      5.0 mL 
1.5 M Tris (pH 8.8)                                         2.5 mL 
10% SDS                                                         0.1 mL 
10% APS                                                         0.1 mL 
TEMED                                                       0.004 mL 
 






The mix for running gel (8%) consisted of: 
Water                                                               4.6 mL 
30% Acrylamide mix                                      2.7 mL 
1.5 M Tris (pH 8.8)                                         2.5 mL 
10% SDS                                                         0.1 mL 
10% APS                                                         0.1 mL 
TEMED                                                       0.006 mL 
 
The mix for staking gel (4%) consisted of: 
Water                                                             2.15 mL 
30% Acrylamide mix                                      0.4 mL 
1.0 M Tris (pH 6.8)                                     0.375 mL 
10% SDS                                                       0.03 mL 
10% APS                                                       0.03 mL 
TEMED                                                       0.003 mL 
The samples were loaded in these polyacrylamide gels and 
electrophoresis was made in running buffer 1X at 120 V for 15 minutes 






and at 140 V until the end of the experiment using PowerPac HC Power 
Supply (Bio-Rad). The next step of western blotting was the 
electroblotting on nitrocellulose or PVDF membranes (Amersham 
Protran, GE Healthcare Life Sciences). In this procedure the proteins 
pass from the gel to the membrane, where they are immobilized           
at 380 mA for 90 minutes at 4°C with an appropriate buffer, the transfer 
buffer 1X (25 mM Tris, 192 mM glycine and 20% methanol, pH 8.3). 
The membranes were stained with Ponceau S solution in order to verify 
this transfer, washed with PBS 1X in order to eliminate the staining and 
incubated with a blocking solution, 0.25% or 1% non-fat milk in PBS-T 
(PBS 1X with 0.05% of Tween-20), at 25°C for 1 hour on a shaking 
support. Later, the membranes were incubated overnight at 4°C, on a 
shaking support, with specific primary antibodies: 1:400 anti-β-ACTIN 
(C4) diluted in PBS-T with 5% non-fat milk (Abcam); 1:100                     
anti-ALKALINE PHOSPHATASE (H-300, is recommended for TNAP 
detection) diluted in PBS-T with 5% non-fat milk, 1:100 anti-MRP6 
(H-70) and 1:100 anti-CD73 (IE9) diluted in PBS-T with 0.25%      
non-fat milk (Santa Cruz Biotechnology). The following day, the 
membranes were washed three times for 10 minutes with PBS-T and 
incubate with an appropriate horseradish peroxidase-conjugated 
secondary antibody at room temperature for 1 hour on a shaking 
support. Then, the membranes were washed again three times for 10 
minutes with PBS-T and the protein signals were detected by 
Chemiluminescent Peroxidase Substrate-1 or Super Signal West Femto 
Maximun Sensivity Substrate (Thermo Scientific), using ChemidocTM 






XRS detection system (BioRad) equipped with Image Lab Software for 
the image acquisition (BioRad). A densitometric analysis                  
was performed by using ImageJ software (National Institute of Health, 
Bethesda, MD). The data of a specific protein of each sample           
were normalized with the respective β-actin signal; the protein 
expression level in the control sample is considered equal to 100%. 
Each result   was expressed as percentage of the value of the control 
sample. Each test was repeated three times.  
 
2.17 Migration assay 
The ability of the probenecid to modulate the cell migration rate       
was evaluated by in vitro wound-healing migration assay. For the 
migration assay, 1 x 106 HepG2 cells were seeded in each 35-mm cell 
culture dish (Cellview cell culture dish, 35/10mm glass bottom, Greiner 
Bio-one) and cultured in DMEM containing 10% FBS to promote          
a nearly confluent cell monolayer. Then, a linear wound was generated 
in the cellular monolayer with a sterile 10 μl plastic pipette tip.        
Any cellular debris was removed by washing with PBS 1X and 
replaced with 2 mL of DMEM with 1% FBS containing 250 µM         
of probenecid; DMEM with 1% FBS containing 0.25% of DMSO was 
used as control. The cells were treated for 24 and 48 hours with 
probenecid or DMSO in DMEM with 1% FBS and the time-lapse 
images were obtained using a BioStation IM incubator,                 






version 2 (Nikon) (Fig. 2.12). The images acquired were further 
analysed by using computing software (ImageJ 1.46) and the results of 
migration rate were reported as µm/h. 
 
 Fig. 2.12: BioStation IM incubator, version 2 (Nikon). 
 
2.18 Cellular cycle analysis 
In order to analyse the effects of probenecid on the modulation of the 
HepG2 migration rate was performed an assay to study the cellular 
cycle, as described by Laurenzana et al. [170]. After 24 and 48 hours   
of probenecid treatment (see 2.2), HepG2 cells were detached and 
centrifuged at 1200 rpm for 5 minutes at 4°C. Subsequently the pellet 
was resuspended in 800 µL of PBS 1X, again centrifuged at 1200 rpm 
for 5 minutes at 4°C, then, were removed 700 µL of PBS 1X,             
and the cells resuspended in 100 µL of the remainder PBS 1X. Then, 
the cells were fixed in cold ethanol 70% (drop by drop) for 1 hour, 






then, labeled with propidium iodide (ex./em.: 535/617 nm, 
InvitrogenTM) and RNase staining solution for 30 minutes.                 
The samples were acquired by Navios flow cytometer (Beckman 
Coulter), while, the data were analysed by ModFit LT Software  
(Verity Software House). Furthermore, in order to confirm the data 
obtained on the cellular cycle we performed experiments of Real-Time 
PCR (see 2.15) analysing different transcripts (p16, p21 and p53). 
 
2.19 Imaging assay using confocal microscopy 
An immunofluorescence assay with phalloidin was performed in order 
to analyse the molecular effects of probenecid on the modulation of the 
HepG2 migration rate. The phalloidin is a bicyclic peptide present in 
the plant Amanita Phalloides, and, it is able to link specifically actin 
filaments; it is conjugated with a fluorescent dye visible with                 
a fluorescence microscope. 1.5 × 10
5
 HepG2 cells and 1.1 × 105    
MDA-MB-231 cells were seeded on slides in each well of 12-wells 
plates in 1 mL of DMEM. After 24 hours from their seeding, these cells 
were treated for 24 and 48 hours with 250 µM of probenecid or with 
0.25% of DMSO. After the treatment, the medium was removed, and, 
after one wash with PBS 1X, the cells were fixed in 400 µL                  
of 4% paraformaldehyde for 10 minutes at room temperature.                    
After three washes with PBS 1X, the cells were permeabilized with 






Triton X-100 0.5% in PBS 1X for 5 minutes and, after three new 
washes in PBS 1X, blocked in saturation buffer (1% BSA in PBS 1X) 
for 15 minutes at room temperature. Then, the cells were incubated 
with Phalloidin Alexa Fluor 488 (ex./em.: 495/518 nm, InvitrogenTM) 
diluted 1:1000 in saturation buffer for 1 hour at room temperature, in 
the dark. After three washes in PBS 1X, the nuclei were stained with 
1.5 µM of propidium iodide (ex./em.: 535/617 nm, InvitrogenTM) in 
PBS 1X for 10 minutes. Finally, after three washes in PBS 1X, the 
slides were assembled using 90% glycerol in PBS 1X. The images were 
obtained with a confocal fluorescence microscope (Leica TSC-SP2 
HCX PL APO, ×63/1.32-0.60 oil objective) and acquired using the 
Leica Confocal Software W. In these images the actin filaments and the 
filopodia have a green colour and the nuclei have a red colour. 
 
2.20 Statistical analysis 
The data of each experiment were presented as means ± SD. Student’s 
t-test was performed pairwise to compare control and treated samples. 
Each experiment was performed three times. Differences were 
considered significant whenever p-value < 0.05, in particular,            
the following legend was used for the significance of the data: p < 0.05 
(*), p < 0.01 (**), p < 0.001 (***). Statistical analysis was performed 
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Recent studies show that in ABCC6-silenced HepG2 cells there are 
changes in the cellular phenotype as a consequence of gene expression 
dysregulation and alteration in cellular cycle genes [76] [77].         
These data suggest that ABCC6 protein could have other physiological 
roles in the cells besides the well-known role of promoting the PPi 
accumulation outside the cells. In the present scientific research,        
we carried out a series of experiments in order to characterize the 
involvement of ABCC6 in some cellular processes through the use      
of probenecid, an inhibitor of ABC proteins [75]. 
 
3.1 Inhibition of ABCC6 activity by Probenecid in 
HEK293 cells 
In order to quantify the effective inhibition of probenecid on the 
transport activity of the ABCC6 protein, a doxorubicin efflux assay   
was conducted (this compound is a known substrate also transported  
by ABCC6 transporter [20]). This assay was conducted in HEK293 
cells, a cellular line of human embryonic kidney 293 easily transfected, 
stably transfected with ABCC6-Flag-pcDNA and with Flag-pcDNA    
(as control cells), in presence and in absence of 1 mM of probenecid. 
As we can see in Fig. 3.1, the efflux of doxorubicin, in absence            
of probenecid, is significantly higher in ABCC6-Flag-pcDNA cells 
compared with Flag-pcDNA cells, suggesting an involvement              
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of ABCC6 transporter in the release of doxorubicin. In presence           
of probenecid, there is no significant difference in the doxorubicin 
efflux but there is a higher inhibition in doxorubicin efflux in     
ABCC6-Flag-pcDNA cells compared with Flag-pcDNA cells. 
Therefore, probenecid inhibits the transport activity carried out            
by ABCC6 protein [171]. 
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3.2  Effects of Probenecid in HepG2 cells 
Other experiments were performed in HepG2 cells (cells in which 
ABCC6 is abundantly expressed [41], see Fig. 3.31), in order to 
understand the effects of a possible modulation of ABCC6 activity in 
some cellular processes. 
 
3.2.1 Evaluation of cytotoxicity and morphology 
A cytotoxicity assay was initially performed in HepG2 cells, a human 
hepatocellular carcinoma cellular line, in order to evaluate the effects 
time- and dose-dependent of probenecid. Probenecid did not show 
cellular toxicity up to 250 µM within 48 hours (about 90% of viability); 
after 48 hours of treatment at 500 µM the viability is about 70% and    
at 1000 µM the viability is about 50% (Fig. 3.2) [171]. 
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Subsequently, the cells were examined with a phase-contrast 
microscope in order to observe morphological changes induced           
by probenecid. The cells, after the treatment with probenecid, did not 
show noticeable alterations in shape, size and number of vacuoles   
(Fig. 3.3) [171]. 
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3.2.2 Evaluation of intracellular ROS 
An assay was performed in order to evaluate the effects of probenecid 
on intracellular ROS in HepG2 cells. As we can see in Fig. 3.4, 
probenecid, up to 250 µM within 48 hours, did not show significant 
variations of intracellular ROS. 500 and 1000 µM of probenecid 
showed a decrease of about 30% within 24 hours of intracellular ROS; 
the same concentrations within 48 hours did not show significant 
variations of intracellular ROS.  
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3.2.3 Evaluation of inhibition of calcein transport 
After analysing these preliminary results we decided to test 250 µM     
of probenecid (for a short period of time) in HepG2 cells in order to 
check if it could inhibit the transport of calcein by MRPs [17].             
As we can see in Fig. 3.5, in HepG2 cells treated with probenecid    
there is a decrease of about 35% of external calcein and an increase of 
about 40% of internal calcein. These data suggest that all MRPs, 
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including ABCC6 (abundantly expressed in HepG2 cells [41]), are 
inhibited by the presence of probenecid. In fact, in presence of 
probenecid, the calcein, once metabolized inside the cells, can’t be 
expelled outside them. 
 
 
3.2.4 Evaluation of cellular density 
A new experiment shows that ABCC6 and NT5E genes are regulated   
by cellular confluence. As we can see in Fig. 3.6, at about 40%           
of confluence (6 × 10
5
 HepG2 cells, in a well of 6-wells plates)        
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there is a greater expression of ABCC6 gene compared with NT5E 
gene, while, at about 80% of confluence (after 48 hours from a possible 
pharmacological treatment) there is a greater expression of NT5E gene 
compared with ABCC6 gene. These data highlight a possible 
correlation between the two genes; in particular ABCC6 could carry 
some substrates that could promote the expression of CD73, after their 
accumulation. Therefore the use of an ABC inhibitor, as probenecid, 
decreasing the transport activity of the ABCC6 could regulate            
the expression of CD73. This regulation could also regulate different 
phenomena related to these proteins such as mineralization and    
cancer processes.  
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From the analysis of all these preliminary data we decided to use          
in HepG2 cells probenecid at the concentration of 250 µM for              
24 and 48 hours, in order to understand the effects of partial modulation 
of ABCC6 transporter activity. 
 
3.2.5 Effects of treatment with Probenecid for 24 hours 
At first, HepG2 cells were treated with 250 µM of probenecid for        
24 hours. As we can see in Fig. 3.7 there is no significant variations     
in ABCC6 and NT5E expression gene levels via Real-Time PCR, 
although previously we observed an influence of probenecid on          
the activity of the ABCC6 protein. 
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3.2.6 Effects of treatment with Probenecid for 48 hours  
Subsequently, HepG2 cells were treated with 250 µM of probenecid   
for 48 hours. As we can see in Fig. 3.8 there is a significant decrease    




Then, a protein analysis was performed, by western blotting;                 
it confirmed a significant decrease of about 30% of ABCC6 and CD73 
proteins (Fig.3.9) [171]. 
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These data showed a correlation in the levels of the two genes and 
proteins after 48 hours of probenecid treatment. In particular, these data 
support our hypothesis of a functional correlation of the two proteins: 
in presence of a low expression of ABCC6, the levels of expression of 
CD73 decrease. Furthermore, the decreased expression of ABCC6 
protein, caused by probenecid, could promote a smaller outflow of 
ATP, and consequently, the expression of CD73 protein could decrease 
because of a reduced presence of AMP (substrate of CD73), a product 
of ATP catabolism. In this context we also analysed the ENPP1 gene 
expression and TNAP gene and protein expression, both involved in the 
degradation pathway of extracellular ATP. As we can see in Fig. 3.10 
ENPP1 and TNAP gene expression is unchanged after a treatment for 
48 hours with 250 µM of probenecid. 
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After the treatment with probenecid, TNAP  protein remains unchanged 
(Fig. 3.11). 
 
The non-variation of ENPP1 gene suggests that this gene does not 
suffer both of the partial inhibition of ABCC6 protein and the partial 
decrease of ATP efflux in the extracellular space. The expression         
of TNAP, in literature, is inversely related to the expression of CD73; 
in fact, the adenosine produced by CD73 is able to inhibit                   
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the expression of TNAP. In this specific case, we can explain that the 
non-variation of TNAP is strictly related to the CD73 protein decrease. 
This decrease of about 30% would not allow a significant reduction of 
extracellular adenosine and consequently an increase in TNAP 
expression. The treatment with probenecid is able to control different 
processes at cellular level: the partial regulation of ABCC6 protein 
could limit the phenomenon of ectopic mineralization due to a smaller 
amount of ATP carried out in the extracellular space. The partial 
regulation of CD73 protein could also decrease the phenomenon of 
cancer progression. The non-activation of TNAP could limit both the 
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Finally, we verified via Real-Time PCR if the treatment with 




No changes, after probenecid treatment, were observed in the transcript 
levels of the other ABC genes analysed [171]. In particular, probenecid 
is only able to decrease the ABCC6 gene and protein expression. 
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3.2.7 Effects of adenosine and ATP on the modulation of 
ABCC6 and CD73 expression  
After verifying, in HepG2 cells, both a modulatory effect of   
probenecid on the activity and protein expression of ABCC6              
and a modulation of CD73 protein expression, we performed other 
experiments in order to characterize the correlation between these two 
proteins. It is known that ABCC6 protein is indirectly involved in the 
production of extracellular adenosine (thanks to ENPP1 and CD73 
proteins); therefore it could have a role in the activation of the 
purinergic system, that is able to control important cellular functions in 
the liver (Fig. 3.13) [171].  
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In these experiments, we verified a possible modulation of ABCC6 and 
CD73 by some purinergic mediators such as adenosine and ATP, in 
presence and in absence of probenecid. This set of experiments        
was performed in order to check if ABCC6 protein is involved in the 
purinergic pathway. In the Fig. 3.14, the effects of adenosine and 
probenecid were observed on CD73 expression in HepG2 cells after    
48 hours of treatment. CD73 protein levels were reduced of about 30% 
after treatment of cells only in presence of probenecid. Moreover, 
CD73 protein levels are increased by about 30% and 40% after 
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treatment respectively with 10 and 100 µM of adenosine. Finally, 
CD73 protein levels are decreased by about 10% if probenecid is added 
to treatment with adenosine [171].  
 
Then, as ATP is a possible substrate transported by ABCC6 protein, 
HepG2 cells were incubated for 48 hours with different concentrations 
of ATP, in presence and in absence of probenecid (Fig. 3.15). Also in 
this case, CD73 protein levels are decreased only in presence of 
probenecid; after a treatment with 50 and 500 µM of ATP, CD73 
protein levels are increased respectively of about 20 and 60%. Finally, 
CD73 protein levels are decreased of about 10% if probenecid is added 
to treatment with ATP [171]. 
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The Fig. 3.16 shows the effects of adenosine, in HepG2 cells,              
on ABCC6 protein expression after 48 hours of treatment. Also in this 
case, ABCC6 protein levels are decreased of about 30% only in 
presence of probenecid. After a treatment with 10 and 100 µM             
of adenosine, ABCC6 protein levels are increased respectively of about 
30 and 50%, while, ABCC6 protein levels are slightly decreased if 
probenecid is added to the treatment with adenosine [171]. 
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These data show that probenecid, an ABC transporters inhibitor, 
decreases CD73 protein levels, while, the adenosine increases CD73 
expression in HepG2 cells. The same result was obtained by adding 
ATP, an ABCC6 substrate, to HepG2 cells; ATP is able to restore the 
levels of adenosine. These results suggest that ABCC6, promoting the 
efflux of ATP outside the cells, provides to the extracellular 
compartment both PPi, necessary to prevent the calcification processes, 
and purine nucleotides and adenosine, key mediators of many 
physiological processes [124] [125]. The decrease of ABCC6 and 
CD73 protein levels thanks to probenecid and their increase thanks to 
ATP and adenosine, could suggest both a role of ABCC6 in the 
regulation and in the activation of the purinergic system and in the 
overlapping of clinical symptoms of ACDC and PXE diseases.    
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Finally, we could not exclude the possible involvement of ABCC6 
protein, through the purinergic system, in other liver diseases. 
 
3.2.8 Effects of CD73 modulation by Probenecid  
It is known in literature that CD73 protein is an important key regulator 
in some cancer processes, in particular in growth and cancer metastasis 
[103] [104]. CD73 protein thanks to its ability to promote the migration 
and invasion of cancer cells, could be an excellent candidate for 
anticancer therapy. As we have already noted in previous experiments, 
it is possible to decrease NT5E gene and CD73 protein expression using 
probenecid. In order to verify the possible phenotypic changes 
produced by CD73 decrease and by the partial decrease of purinergic 
system, HepG2 cells were treated with 250 µM of probenecid for 24 
and 48 hours in a migration assay called wound-healing. It was 
important to check if, in addition to a decrease of NT5E gene and CD73 
protein expression, there was also a consequent variation of the 
migration cellular processes. As we can see in Fig. 3.17 we found both 
no variation in migration rate of HepG2 cells treated for 24 hours with 
probenecid and no changes in NT5E gene levels (see 3.2.1 session). As 
we can see in Fig. 3.17 we found a significant decrease in migration 
rate of HepG2 cells after 48 hours of treatment with probenecid. In 
particular, there is a decrease of about 40% in migration rate of these 
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cells between 24 and 48 hours of treatment, in accordance with a 
decrease in NT5E gene expression and in CD73 protein levels after 48 
hours of treatment with probenecid  (see 3.2.2 session).  
 
Therefore, we can hypothesize a correlation between the CD73 protein 
expression level and the migration rate of HepG2 cells. 
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3.2.9 Evaluation of the mechanism promoting the 
decrease of  HepG2 cells migration rate  
Subsequently experiments were performed in order to understand          
a possible mechanism underlying the control of migration speed           
of HepG2 cells after a treatment with probenecid. A first experiment 
was performed on HepG2 cells treated with 250 µM of probenecid for 
24 and 48 hours, in order to analyse their cellular cycle, using the flow 
cytometer. In the following figures, Fig. 3.18 and Fig. 3.19, we can see 
the results of the cellular cycle analysis, respectively after 24 and 48     
hours of the treatment with probenecid. As stressed in these figures 
there is no block of the cellular cycle in any specific phase and the 
population of untreated and treated cells in each phase is always the 
same. Consequently probenecid seems not to act on the slowing of the 
cellular cycle. 
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In order to confirm the cellular cycle data, we performed an analysis of 
p16, p21 and p53 expression gene levels, via Real-Time PCR,          
after 250 µM of the treatment with probenecid for 48 hours. p16, p21 
and p53 proteins are able to inhibit the action of cyclin-dependent 
kinases (CDKs), and to block the cellular cycle. As we can see in      
Fig. 3.20, we found no significant variations of expression of these 




Then we performed an experiment in order to evaluate a possible 
modification of actin filaments, the main components of the 
cytoskeleton architecture and therefore of important cellular functions 
as the cellular movement. In order to study these modifications,           
an immunofluorescence assay was performed using the phalloidin,       
a bicyclic peptide, that specifically binds with actin filaments.           
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The cells were treated with 250 µM of probenecid for 24 and 48 hours. 
As we can see in Fig. 3.21, in the cells treated with DMSO (as control 
cells) and with 250 µM of probenecid for 24 hours there are no 
significant differences: these cells are not very compact and have many 
filopodia (green), that extend in all directions. Instead, in the cells 
treated with 250 µM of probenecid for 48 hours there are significant 
changes: the cells are very compact and the filopodia (green) are almost 
completely absent or, if present, they are very short. In addition, the 
actin filaments (green), which are depolymerized, are almost entirely 
concentrated in the periphery of the cells. Therefore we can deduce that 
probenecid, if used at the concentration of 250 µM for 48 hours, is able 
to decrease the cellular movement and to promote significant changes 
on the actin filaments and on the filopodia. Therefore the use of 
probenecid could be very important to decrease, in this type of cancer, 
the migration and metastasis processes. 
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3.3 Effects of Quercetin and Doxorubicin in 
HepG2 cells 
In order to highlight the correlation between the ABCC6 and NT5E 
genes, we performed experiments on HepG2 cells with doxorubicin and 
quercetin, two compounds involved in the activity and in the regulation 
of MRP proteins [20] [165]. 
 
3.3.1 Effects of Quercetin 
We performed in HepG2 cells an experiment with quercetin, another 
inhibitor of some multidrug resistance-associated proteins, MRPs 
[165]. A cytotoxicity assay was initially performed on HepG2 cells in 
order to evaluate the effects time- and dose-dependent of quercetin.    
As we can see in Fig. 3.22, the quercetin does not show cellular 
toxicity up to 165 µM within 24 hours (about 95% of viability). After a 
treatment of 48 hours the cellular viability decreases of about 25% and 
the cells  become smaller. At 330 and 660 µM of quercetin 
concentrations, the cells progressively reduce their viability and show 
significant morphological changes. 
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After analysing these preliminary results we decided to test 165 µM     
of calcein (for a short period of time) in HepG2 cells in order to check 
if this compound was able to inhibit the transport of calcein by MRPs 
[17]. As we can see in Fig. 3.23, in HepG2 cells treated with the 
quercetin we found a decrease of external calcein (of about 20%) and 
an increase of internal calcein (of about 30%). These data suggest that 
all MRPs, including ABCC6 (abundantly expressed in HepG2 cells), 
are inhibited by the presence of quercetin. In fact, in presence                
of quercetin, the calcein, once metabolized inside the cells, can’t be 
expelled outside them. Analysing these data we can deduce that 
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quercetin is less able to inhibit the ABCs transport activity than 
probenecid in these cells.  
 
After the analysis of all these preliminary data we decided to use in 
HepG2 cells the quercetin at the concentration of 165 µM for 24 hours, 
in order to understand the cellular variations in conditions of partial 
modulation of ABCC6 transporter activity. After the quercetin 
treatment, as we can see in Fig. 3.24, we found a slightly variation in 
ABCC6 and NT5E expression gene levels via Real-Time PCR, although 
we previously observed an influence of quercetin on the activity of 
ABCC6 protein. 
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The results obtained after 24 hours of the quercetin treatment,               
in HepG2 cells, are similar to those ones obtained previously using 
probenecid. Therefore, these data show similar cellular effects using 
different ABC proteins inhibitors in HepG2 cells and also confirm the 
correlation between the ABCC6 and NT5E genes. 
 
3.3.2 Effects of Doxorubicin  
We performed in HepG2 cells an experiment with doxorubicin,             
a substrate of ABC proteins [20]. The cells were treated for several 
days with increasing concentrations of doxorubicin in order to allow an 
adaptation of the cells to this compound and at the same time to 
evaluate possible variations in the gene expression of some MRP 
transporters. As we can see in Fig. 3.25, this treatment is able to 
determine a cellular line resistant to doxorubicin and to increase         
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the ABC gene expression; specifically, there is a dose-dependent 
increase in ABCB1 and ABCC6 genes. Moreover, we found again          




The doxorubicin and the inhibitors of MRPs protein, the probenecid 
and the quercetin in HepG2 cells are able to modulate respectively 
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3.4 Effects of Probenecid in other cellular lines 
Finally, we performed some experiments in order to verify whether 
probenecid was able to produce the same results in other cellular types, 
in particular we focused our attention on the control of CD73 
expression. So, we tested probenecid, adenosine and ATP on HuH-7, 
MDA-MB-231 and HEK293 cellular lines. 
 
3.4.1 Effects of Probenecid in HuH-7 cells 
A cytotoxicity assay was initially performed in HuH-7 cells, a cellular 
line of human hepatocellular carcinoma more differentiated than 
HepG2 cells, in order to evaluate the effects time- and dose-dependent 
of probenecid. Probenecid did not show cellular toxicity up to 250 µM 
within 48 hours (about 85% of viability); after 48 hours of treatment 
with probenecid at 500 µM the viability is about 80% and at 1000 µM 
the viability is about 60% (Fig. 3.26). The cells after the treatment with 
probenecid did not show significant alterations in their morphology. 
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After analysing these preliminary results we decided to test 250 µM     
of probenecid (for a short period of time) in HuH-7 cells in order to 
check if this compound was able to inhibit the transport of calcein       
by MRPs [17]. As we can see in Fig. 3.27, in HuH-7 cells treated with 
probenecid there is a decrease of about 20% of external calcein and an 
increase of about 15% of internal calcein. These data suggest that all 
MRPs, including ABCC6, are slightly inhibited by the presence of 
probenecid. In fact, in presence of probenecid, the calcein, once 
metabolized inside the cells, can’t be expelled outside them.  
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Then, we decided to use probenecid in HuH-7 cells at the concentration 
of 250 µM for 48 hours, in order to understand if CD73 protein could 
change its expression levels. As we can see in Fig. 3.28, no significant 
variation in CD73 protein expression was found after the treatment 
with probenecid. 
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We performed other experiments with different concentrations            
of adenosine and ATP, in order to evaluate the correlation between 
these compounds and CD73 expression. At first, the effects of 
adenosine were evaluated in HuH-7 cells after 48 hours of treatment, in 
presence and in absence of probenecid. In Fig. 3.29, CD73 protein 
levels remain unchanged after the treatment of these cells only in 
presence of probenecid. Moreover, CD73 protein levels are increased 
of about 10-20% after the treatment respectively with 10 and 100 µM 
of adenosine. Finally, CD73 protein levels always remain slightly    
over-expressed of about 10-20% if probenecid is added to treatment 
with adenosine.  
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The effects of ATP were evaluated in HuH-7 after 48 hours                  
of treatment, in presence and in absence of probenecid. In Fig. 3.30, 
CD73 protein levels remain unchanged after the treatment of these cells 
only in presence of probenecid, while, CD73 protein levels are 
increased of about 10-20% after the treatment respectively with 50 and 
500 µM of ATP. Finally, CD73 protein levels always remain slightly 
over-expressed of about 10-20% if probenecid is added to treatment 
with ATP. 
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So, in HuH-7 cells we found a poor effect of probenecid, adenosine and 
ATP in CD73 modulation. As we can see in Fig. 3.31, the basal levels 
of ABCC6 gene expression in these cells are lower than those ones in 
HepG2 cells; the amount of ATP and adenosine transported by ABCC6 
could be too low to regulate CD73. The lowest ABCC6 gene expression 
in these cells could explain the poor effect of probenecid. Probably in 
these cells the CD73 protein is less regulated by adenosine and ATP. 
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3.4.2 Effects of Probenecid in MDA-MB-231 cells 
A cytotoxicity assay was initially performed on MDA-MB-231 cells, a 
cellular line of triple-negative human breast cancer poorly 
differentiated, in order to evaluate the effects time- and dose-dependent 
of probenecid. This cellular line is characterized by high levels             
of NT5E gene (see Fig. 3.31), and a partial control of CD73 protein by 
probenecid could promote a decrease of cancer processes. Probenecid 
did not show cellular toxicity up to 250 µM within 48 hours (about 
90% of viability); after 48 hours of treatment with probenecid at 500 
µM the viability is about 80% and at 1000 µM the viability is about 
60% (Fig. 3.32). The cells after the treatment with probenecid did not 
show significant alterations in their morphology. 
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We decided to test 250 µM of probenecid (for a short period of time)    
in MDA-MB-231 cells in order to check if this compound was able to 
inhibit the transport of calcein by MRPs [17]. As we can see in        
Fig. 3.33, in MDA-MB-231 cells treated with probenecid we did not 
find any significant variation both in the amount of external and 
internal calcein. These data suggest that the MRPs are not inhibited     
by the presence of probenecid. In fact, in presence of probenecid,        
the calcein, once metabolized inside the cells, can be normally expelled 
outside them. 
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In MDA-MB-231 cells we found no effect of probenecid in the 
modulation of MRPs activity. As previously seen in Fig. 3.31,            
the lowest ABCC6 expression, in these cells compared to HepG2 and 
HuH-7 cells could explain this effect. Then, we decided to use in 
MDA-MB-231 cells the probenecid at the concentration of 250 µM for 
48 hours, in order to understand if CD73 protein could change its 
expression levels and to further correlate the modulation of CD73 via 
ABCC6. As we can see in Fig. 3.34, we found no significant variation 
in CD73 protein expression after the treatment with probenecid. 
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We performed experiments with different concentrations of adenosine 
and ATP, in order to evaluate the correlation between these compounds 
and CD73 expression. At first, the effects of adenosine were evaluated 
in MDA-MB-231 cells after 48 hours of treatment, in presence and      
in absence of probenecid. In Fig. 3.35, CD73 protein levels remain 
unchanged after the treatment of these cells only in presence                
of probenecid. Moreover, CD73 protein levels are increased of about 
15-20% after the treatment respectively with 10 and 100 µM               
of adenosine. Finally, CD73 protein levels always remain slightly   
over-expressed of about 15-20% if probenecid is added to the treatment 
with adenosine.  
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Then, the effects of ATP were evaluated in MDA-MB-231 cells after 
48 hours of treatment, in presence and in absence of probenecid.          
In Fig. 3.36, CD73 protein levels remain unchanged after the treatment 
of these cells only in presence of probenecid, while, CD73 protein 
levels are increased of about 20-25% after the treatment respectively 
with 50 and 500 µM of ATP. Finally, CD73 protein levels always 
remain slightly over-expressed of about 20-25% if probenecid is added 
to the treatment with ATP. 
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So, in MDA-MB-231 cells we found no effect of probenecid and a poor 
effect of adenosine and ATP in CD73 modulation. As previously seen 
in Fig. 3.31, the lowest ABCC6 expression, in these cells could explain 
no effect of probenecid. In this context, probably the CD73 protein is 
less regulated by adenosine and ATP because the basal levels of 
ABCC6 expression in these cells are very lower than those ones in 
HepG2 and HuH-7 cells. So, the amount of ATP and adenosine 
transported by ABCC6 could be too low to regulate CD73. In order to 
validate the results obtained with probenecid, we performed an 
experiment on the possible modifications of actin filaments. An 
immunofluorescence assay was performed using the phalloidin, that is 
able to highlight possible molecular changes on the actin filaments 
induced by a treatment with 250 µM of probenecid for 48 hours. As we 
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can see in Fig. 3.37, these cells, more elongated and isolated than 
HepG2 cells, do not show any alterations after treatment with 
probenecid: the filopodia (green) are long and always present, while the 
actin filaments (green) are present on the whole cellular surface; 
therefore probenecid could not able to decrease the cellular migration 
in these cells. We can correlate these results with those ones obtained 
with CD73 modulation after the treatment with probenecid: the possible 
non-reduction of MDA-MB-231 migration rate could be caused by the 
non-reduction of CD73 and not significant morphological changes. 
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3.4.3 Effects of Probenecid in HEK293 cells  
A cytotoxicity assay was initially performed in HEK293 cells, a 
cellular line of human embryonic kidney 293, in order to evaluate       
the effects time- and dose-dependent of probenecid. Probenecid did not 
show cellular toxicity up to 250 µM within 48 hours (about 90% of 
viability); after 48 hours of treatment with probenecid at 500 µM the 
viability is about 80% and at 1000 µM the viability is about 70%    
(Fig. 3.38). These cells are more resistant to probenecid than other kind 
of cells examined. These cells after the treatment with probenecid did 
not show significant alterations in their morphology. 
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As previously seen in Fig. 3.1, in HEK293 cells transfected with only 
Flag-pcDNA and treated with probenecid we found a small decrease     
of doxorubicin efflux. This datum suggests that the MRPs are slightly 
inhibited by the presence of probenecid. Then, we decided to use in 
these cells probenecid at the concentration of 250 µM for 48 hours,      
in order to understand if CD73 protein could change its expression 
levels. As we can see in Fig. 3.39, we found no significant variations in 
CD73 protein expression after the treatment with probenecid. 
 
We performed other experiments with different concentrations             
of adenosine and ATP, in order to evaluate a possible correlation 
between these compounds and CD73 expression. At first, the effects of 
adenosine were evaluated in HEK293 cells after 48 hours of treatment, 
in presence and in absence of probenecid. In Fig. 3.40, CD73 protein 
levels remain unchanged after the treatment of these cells only              
in presence of probenecid. Moreover, CD73 protein levels are increased 
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of about 15% after treatment respectively with 10 and 100 µM             
of adenosine. Finally, CD73 protein levels remain unchanged                
if probenecid is added to the treatment with adenosine.  
 
Then, the effects of ATP were evaluated in HEK293 after 48 hours      
of treatment, in presence and in absence of probenecid. In Fig. 3.41, 
CD73 protein levels remain unchanged after the treatment of these cells 
only in presence of probenecid, while CD73 protein levels are 
increased of about 20% after treatment respectively with 50 and        
500 µM of ATP. Finally, CD73 protein levels always remain slightly 
over-expressed of about 10-20% if probenecid is added to treatment 
with ATP. 
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In this cellular line we obtained the same results of HuH-7 cellular line 
treated with probenecid, adenosine and ATP. In HEK293 cells             
we found a poor effect of probenecid, adenosine and ATP in CD73 
modulation. As previously seen in Fig. 3.31, the lowest ABCC6 
expression could explain the poor effect of probenecid. In these cells, 
probably, the CD73 protein expression is slightly regulated                  
by adenosine and ATP because the basal levels of ABCC6 expression in 
these cells are lower than those ones in HepG2 cells. So, the amount of 




























ABCC6 protein, belonging to sub-family C of ABC transporters,          
is codified by ABCC6 gene and it is mainly expressed in the liver and 
the kidney, in particular at level of basolateral membrane [41]. It is also 
probably involved in determining low levels of resistance to some 
drugs. ABCC6 mutations cause a rare recessive disease called 
Pseudoxanthoma Elasticum, characterized by ectopic calcification       
of connective fibers [112]; the mutations of ABCC6 in PXE stress the 
role of this protein in the ectopic mineralization processes. The aim     
of this scientific research is to characterize the role of ABCC6 protein 
in particular in the activation of purinergic system and in the cancer 
processes. The research is based on two evidences. The first one 
concerns how the stable transfection with ABCC6 gene in HEK293 
cells is able to promote a major efflux of ATP in extracellular space 
[119] [120]; ATP consequently produces PPi and other molecules, such 
as AMP, adenosine and Pi, involved in the balance both                       
of mineralization and of purinergic processes. The second one concerns 
how, using AOPCP, a CD73 inhibitor, it is possible to partially reduce 
MDR phenotype in GBM cells by the expression and the activity         
of MRP1 modulation [163]. It could be possible to control CD73 
protein expression using an inhibitor of MRPs protein, such as 
probenecid. In this scientific research, we performed a set of 
experiments in order to evaluate the function of ABCC6 in the 
processes previously mentioned and in particular to verify the 
correlation between ABCC6 and CD73 proteins. CD73 is a protein 
involved in cancer processes and in the pathway metabolizing the 






extracellular ATP also carried out by ABCC6. We performed a 
preliminary experiment in order to verify if the transport activity of 
ABCC6 was significant decreased with probenecid in HEK293 cells 
stably transfected with ABCC6-Flag-pcDNA; specifically ABCC6 
activity was partially inhibited by probenecid [171]. Then, we 
performed an experiment with probenecid in HepG2 cells, a cellular 
line of human hepatocellular carcinoma in which ABCC6 is very 
expressed. The results showed both a significant decrease of about 30% 
of MRPs activity and of about 30% of ABCC6 protein after a treatment 
with 250 µM of probenecid for 48 hours [171]. Therefore, it is possible 
to control the expression and activity of ABCC6 protein by probenecid. 
CD73 protein expression decreases of about 30% [171] while TNAP 
protein remains unchanged. The role of probenecid in HepG2 cells       
is important because: it is able to regulate ABCC6 expression and also 
other MRPs activity, probably decreasing the possible effects              
of multidrug resistance; it is able to regulate CD73 expression probably 
decreasing the cancer processes and the amount of extracellular Pi;        
it is not able to determine changes in TNAP expression and 
subsequently not to promote an accumulation of Pi. Then,                   
we performed experiments in presence of adenosine and ATP and 
observed an increase of about 20-60% of ABCC6 and CD73 proteins 
after a treatment with 10 and 100 µM of adenosine and a new treatment 
with 50 and 500 µM of ATP for 48 hours [171]. These data suggest an 
important role of ABCC6 protein in regulating and in particular in the 
activation of purinergic system, one of the major players in supplying 






this system of adenosine and ATP. ATP, a possible physiological 
substrate of ABCC6, is able to increase CD73 protein: this datum could 
explain the correlation between ABCC6 and CD73 proteins.              
This correlation is also confirmed by treating HepG2 cells with 
quercetin and doxorubicin, two compounds able to slightly decrease 
and significantly increase these proteins. In order to verify if there was 
a correlation between the decrease of CD73 and its ability to promote 
cellular migration in cancer cells, we performed a wound-healing assay. 
This migration assay showed a significant decrease of about 40% of 
cellular migration, maybe, due to a down-regulation of CD73.          
This decrease of HepG2 migration rate does not depend on the 
probenecid’s ability to block the cellular cycle (no significant change in 
p16, p21 and p53 gene expression was observed). Another experiment 
shows that the decrease of HepG2 migration rate is correlated with 
significant changes of the arrangement of depolymerized actin 
filaments and of filopodia. Finally, in order to confirm the correlation 
between ABCC6 and CD73 were performed other experiments using 
probenecid, adenosine and ATP in HuH-7, HEK293 and                
MDA-MB-231 cells; these cellular lines express less ABCC6 than that 
one expressed in HepG2 cells. The results obtained in these cells show 
that there are poor effects of probenecid to inhibit the MRPs, including 
ABCC6 protein, and to decrease CD73 expression. This data could be 
correlated with a less expression of ABCC6 in these cells than that one 
expressed in HepG2 cells. The poor effects of probenecid in    
modulation of ABCC6 transporter activity and in controlling of CD73 






expression in MDA-MB-231 cells were also confirmed by observing no 
significant morphological changes in actin filaments and in filopodia. 
Therefore probenecid may not be able to decrease the cellular 
migration in these cells. Furthermore in HuH-7, HEK293 and        
MDA-MB-231cells the adenosine and ATP slightly increase CD73 
levels. From the analysis of all these data emerges a significant role of 
ABCC6 protein in the regulation of processes above mentioned, and in 
particular in controlling of CD73 expression and functionality.             
In conclusion, the ABCC6 transporter is involved in the activation of 
the purinergic system, as it supplies of ATP the extracellular space, 
where are located the purinergic receptors; this datum was confirmed 
both with the addition of probenecid alone and with the addition of 
adenosine and ATP and confirmed in various cellular lines expressing 
ABCC6 differently. This result raises new perspectives on the 
possibility of inhibiting the purinergic system with all the positive and 
negative consequences deriving from it and its importance on the 
immune system. Further experiments are needed however to clarify                  
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